1
|
Imoto S, Suzukawa M, Takada K, Watanabe S, Isao A, Nagase T, Nagase H, Ohta K. Relationship between serum IgA levels and low percentage forced expiratory volume in the first second in asthma. J Asthma 2024:1-8. [PMID: 38376485 DOI: 10.1080/02770903.2024.2321306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Accepted: 02/15/2024] [Indexed: 02/21/2024]
Abstract
Objective: Immunoglobulin A (IgA) is suggested to have pathogenic effects in respiratory inflammatory diseases, including asthma. We aimed to analyze the relationship between serum IgA, and clinical indicators and biomarkers of asthma.Methods: This study was a post hoc analysis of the NHOM Asthma Study. In this study, serum IgA was measured using serum samples stored. We determined an association between the serum IgA level and clinical variables and biomarkers using multivariate linear regression and analyzed the differences in clinical indices between IgA high- and IgA low-asthma.Results: In this study, 572 patients with asthma were included in the final analysis. Lower percentage forced expiratory volume in the first second (%FEV1), higher serum eotaxin levels, lower serum ST2 levels, and higher serum MIP-1β levels, were independently and significantly associated with higher serum IgA levels among asthma patients by multivariate linear regression analysis (%FEV1, 95% confidence interval [CI], -8.18- -0.613, p < 0.05; eotaxin, 95% CI, 8.95-46.69, p < 0.001; ST2, 95% CI, -73.71- -7.37, p < 0.05; and MIP-1β, 95% CI, 1.47-18.71, p < 0.05). Furthermore, IgA high-asthma (serum IgA ≥ 238 mg/dL, n = 270) and IgA low-asthma (serum IgA < 238 mg/dL, n = 302) were compared separately. %FEV1 was significantly lower, the percentage of atopy was higher, and serum MIP-1β level was higher in IgA high-asthma.Conclusions: This study suggests that serum IgA may be involved in the worsening of asthma outcomes, as assessed by %FEV1 and enhanced inflammation via elevated serum MIP-1β.
Collapse
Affiliation(s)
- Sahoko Imoto
- National Hospital Organization, Tokyo National Hospital, Tokyo, Japan
- Department of Medicine, Division of Respiratory Medicine and Allergology, Teikyo University, Tokyo, Japan
| | - Maho Suzukawa
- National Hospital Organization, Tokyo National Hospital, Tokyo, Japan
| | - Kazufumi Takada
- National Hospital Organization, Tokyo National Hospital, Tokyo, Japan
- Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Shizuka Watanabe
- National Hospital Organization, Tokyo National Hospital, Tokyo, Japan
- Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan
| | - Asari Isao
- National Hospital Organization, Tokyo National Hospital, Tokyo, Japan
| | - Takahide Nagase
- Department of Respiratory Medicine, The University of Tokyo, Tokyo, Japan
| | - Hiroyuki Nagase
- Department of Medicine, Division of Respiratory Medicine and Allergology, Teikyo University, Tokyo, Japan
| | - Ken Ohta
- National Hospital Organization, Tokyo National Hospital, Tokyo, Japan
- Japan Anti-Tuberculosis Association, JATA Fukujuji Hospital, Tokyo, Japan
| |
Collapse
|
2
|
Watanabe S, Suzukawa M, Tashimo H, Ohshima N, Asari I, Takada K, Imoto S, Nagase T, Ohta K. Low Serum IL-18 Levels May Predict the Effectiveness of Dupilumab in Severe Asthma. Intern Med 2024; 63:179-187. [PMID: 37225484 PMCID: PMC10864083 DOI: 10.2169/internalmedicine.1808-23] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Accepted: 04/10/2023] [Indexed: 05/26/2023] Open
Abstract
Objective Dupilumab, a monoclonal antibody specific for the human interleukin (IL)-4 receptor α, is used to treat severe asthma, especially in patients with elevated blood eosinophil counts and fractional exhaled nitric oxide (FeNO). The therapeutic response to dupilumab is highly variable. In this study, we explored new serum biomarkers to accurately predict the effect of dupilumab and examine the effect of dupilumab based on changes in the clinical parameters and cytokine levels. Methods Seventeen patients with severe asthma treated with dupilumab were enrolled. Responders, defined as those with a >0.5-point decrease in the Asthma Control Questionnaire (ACQ) score after 6 months of treatment, were included. Results There were 10 responders and 7 non-responders. Serum type 2 cytokines were equivalent between responders and non-responders; the baseline serum IL-18 level was significantly lower in responders than in non-responders (responders, 194.9±51.0 pg/mL; non-responders, 323.4±122.7 pg/mL, p=0.013). The cut-off value of IL-18 at 230.5 pg/mL could be used to distinguish non-responders from responders (sensitivity 71.4, specificity 80.0, p=0.032). Conclusion A low baseline serum IL-18 level may be a useful predictor of an unfavorable response to dupilumab in terms of the ACQ-6.
Collapse
Affiliation(s)
- Shizuka Watanabe
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, Japan
- Department of Respiratory Medicine, The University of Tokyo, Japan
| | - Maho Suzukawa
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, Japan
- Asthma, Allergy and Rheumatology Center, National Hospital Organization Tokyo National Hospital, Japan
| | - Hiroyuki Tashimo
- Asthma, Allergy and Rheumatology Center, National Hospital Organization Tokyo National Hospital, Japan
| | - Nobuharu Ohshima
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan
| | - Isao Asari
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, Japan
| | - Kazufumi Takada
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, Japan
- Department of Geriatric Medicine, The University of Tokyo, Japan
| | - Sahoko Imoto
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, Japan
- Department of Respiratory Medicine, The University of Tokyo, Japan
| | - Takahide Nagase
- Department of Respiratory Medicine, The University of Tokyo, Japan
| | - Ken Ohta
- Department of Respiratory Medicine, The University of Tokyo, Japan
- Department of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Japan
| |
Collapse
|
3
|
Takada K, Suzukawa M, Igarashi S, Uehara Y, Watanabe S, Imoto S, Ishii M, Morio Y, Matsui H, Akishita M, Ohta K. Serum IgA augments adhesiveness of cultured lung microvascular endothelial cells and suppresses angiogenesis. Cell Immunol 2023; 393-394:104769. [PMID: 37741001 DOI: 10.1016/j.cellimm.2023.104769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 09/11/2023] [Accepted: 09/15/2023] [Indexed: 09/25/2023]
Abstract
Immunoglobulin A (IgA) is important in local immunity and is also abundant in the blood. This study aimed to evaluate the effects of serum IgA on cultured lung microvascular endothelial cells (HMVEC-Ls), which are involved in the pathogenesis of inflammatory lung diseases. Serum IgA induced adhesion molecules and inflammatory cytokine production from HMVEC-Ls, and enhanced adhesion of peripheral blood mononuclear cells to HMVEC-Ls. In contrast, migration, proliferation, and tube formation of HMVEC-Ls were significantly suppressed by serum IgA. Experiments with siRNAs and western blotting revealed that two known IgA receptors, β1,4-galactosyltransferase 1 (b4GALT1) and asialoglycoprotein receptor 1 (ASGR1), and mitogen-activated protein kinase and nuclear factor-kappa B pathways were partly involved in serum IgA-induced cytokine production by HMVEC-Ls. Collectively, serum IgA enhanced cytokine production and adhesiveness of HMVEC-L, with b4GALT1 and ASGR1 partially being involved, and suppressed angiogenesis. Thus, serum IgA may be targeted to treat inflammatory lung diseases.
Collapse
Affiliation(s)
- Kazufumi Takada
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan; Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
| | - Maho Suzukawa
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan.
| | - Sayaka Igarashi
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan
| | - Yuuki Uehara
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan; Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan
| | - Shizuka Watanabe
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan; Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
| | - Sahoko Imoto
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan; Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan
| | - Masaki Ishii
- Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
| | - Yoshiteru Morio
- Department of Respiratory Medicine, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan
| | - Hirotoshi Matsui
- Department of Respiratory Medicine, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan
| | - Masahiro Akishita
- Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
| | - Ken Ohta
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan; Japan Anti-Tuberculosis Association, JATA Fukujuji Hospital, 3-1-24 Matsuyama, Kiyose-City, Tokyo 204-8522, Japan.
| |
Collapse
|
4
|
Imoto S, Suzukawa M, Fukutomi Y, Kobayashi N, Taniguchi M, Nagase T, Ohta K. Phenotype characterization and biomarker evaluation in moderate to severe type 2-high asthma. Asian Pac J Allergy Immunol 2023. [PMID: 37302094 DOI: 10.12932/ap-021222-1510] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
BACKGROUND There are two major pathological phenotypes of asthma, type 2 (T2)-high and T2-low asthma, which are important in determining treatment strategies. However, the characteristics and phenotypes of T2-high asthma have not yet been fully identified. OBJECTIVE This study aimed to identify the clinical characteristics and phenotypes of patients with T2-high asthma. METHODS This study used data from a nationwide asthma cohort study in Japan, NHOM Asthma Study. T2-high asthma was defined as a blood eosinophils count ≥ 300 /μL and/or fractional exhaled nitric oxide level ≥ 25 ppb, and the clinical characteristics and biomarkers were compared between T2-high and T2-low asthma. Furthermore, T2-high asthma was phenotyped via hierarchical cluster analysis using Ward's method. RESULTS Patients with T2-high asthma were older, less likely to be female, had longer asthma duration, had lower pulmonary function, and had more comorbidities, including sinusitis and SAS. Patients with T2-high asthma showed higher serum thymus and activation-regulated chemokine and urinary leukotriene E4 levels and lower serum ST2 levels than those with T2-low asthma. There were four phenotypes among patients with T2-high asthma: Cluster 1 (youngest, early-onset, and atopic), Cluster 2 (long duration, eosinophilic, and low lung function), Cluster 3 (elderly, female-dominant, and late-onset), and Cluster 4 (elderly, late-onset, and asthma-COPD overlap-dominant). CONCLUSIONS Patients with T2-high asthma have distinct characteristics and four distinct phenotypes, in which eosinophil-dominant Cluster 2 is the most severe phenotype. The present findings may be useful in precision medicine for asthma treatment in the future.
Collapse
Affiliation(s)
- Sahoko Imoto
- National Hospital Organization Tokyo National Hospital, Tokyo, Japan
- Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Maho Suzukawa
- National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Yuma Fukutomi
- Clinical Research Center, National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan
| | | | - Masami Taniguchi
- Clinical Research Center, National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan
- Shonan Kamakura General Hospital, Kanagawa, Japan
| | - Takahide Nagase
- Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - Ken Ohta
- National Hospital Organization Tokyo National Hospital, Tokyo, Japan
- Japan Anti-Tuberculosis Association, Fukujuji Hospital, Tokyo, Japan
| |
Collapse
|
5
|
Watanabe K, Suzukawa M, Kawauchi-Watanabe S, Igarashi S, Asari I, Imoto S, Tashimo H, Fukami T, Hebisawa A, Tohma S, Nagase T, Ohta K. Leptin-producing monocytes in the airway submucosa may contribute to asthma pathogenesis. Respir Investig 2023; 61:5-15. [PMID: 36369154 DOI: 10.1016/j.resinv.2022.09.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2022] [Revised: 09/21/2022] [Accepted: 09/27/2022] [Indexed: 11/10/2022]
Abstract
BACKGROUND Obesity leads to an increase in the incidence and severity of asthma. Adipokines, such as leptin, secreted by adipocytes induce systemic inflammation, causing airway inflammation. We previously reported that leptin activates both inflammatory and structural cells, including lung fibroblasts. However, little is known about the differential leptin expression and responsiveness to leptin in asthmatic individuals and healthy controls (HC). In this study, we investigated the expression and origin of leptin in asthmatic airways. We also compared the effect of leptin on asthmatic and HC fibroblasts. METHODS Lung specimens from asthmatic and non-asthmatic patients were analyzed by immunohistochemical staining using anti-leptin and anti-CD163 antibodies. Leptin mRNA and protein levels in human monocytes were detected by real-time PCR and western blotting and ELISA, respectively. We used flow cytometry to analyze asthmatic and HC lung fibroblasts for leptin receptor (Ob-R) expression. Further, we determined cytokine levels using cytometric bead array and ELISA and intracellular phosphorylation of specific signaling molecules using western blotting. RESULTS Asthma specimens displayed accumulation of leptin-positive inflammatory cells, which were also positive for CD163, a high-affinity scavenger receptor expressed by monocytes and macrophages. Leptin expression was observed at both transcript and protein levels in human blood-derived monocytes. No significant differences were observed between asthmatic and HC lung fibroblasts in Ob-R expression, cytokine production, and intracellular phosphorylation of p38 mitogen-activated protein kinase. CONCLUSIONS Our findings reveal similar responsiveness of control and asthmatic fibroblasts to leptin. However, the accumulation of inflammatory leptin-producing monocytes in the airway may contribute to the pathogenesis of asthma.
Collapse
Affiliation(s)
- Kaoru Watanabe
- National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan; Department of Respiratory Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
| | - Maho Suzukawa
- National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan.
| | - Shizuka Kawauchi-Watanabe
- National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan; Department of Respiratory Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
| | - Sayaka Igarashi
- National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan
| | - Isao Asari
- National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan
| | - Sahoko Imoto
- National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan; Department of Respiratory Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
| | - Hiroyuki Tashimo
- National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan
| | - Takeshi Fukami
- National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan
| | - Akira Hebisawa
- National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan; Department of Histopathology, Asahi General Hospital, I-1326, Asahi City, Chiba 289-2511, Japan
| | - Shigeto Tohma
- National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan
| | - Takahide Nagase
- Department of Respiratory Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
| | - Ken Ohta
- National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan; Japan Anti-Tuberculosis Association, Fukujuji Hospital, 3-1-24 Matsuyama, Kiyose-City, Tokyo 204-8522, Japan
| |
Collapse
|
6
|
Imoto S, Suzukawa M, Takada K, Watanabe S, Igarashi S, Kitani M, Nagase T, Ohta K. Immunoglobulin A promotes IL-6 and IL-8 production, proliferation, and migration by the human bronchial smooth muscle cells. Cell Immunol 2022; 381:104612. [PMID: 36130412 DOI: 10.1016/j.cellimm.2022.104612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Revised: 08/24/2022] [Accepted: 09/11/2022] [Indexed: 11/03/2022]
Abstract
Immunoglobulin A (IgA) is important in biological defense, mainly in the mucosal area, and plays pathogenic roles in various diseases by activating both inflammatory and structural cells. The current study aimed to validate the effects of IgA on the human bronchial smooth muscle cell (BSMC), which plays a major role in airway inflammation and remodeling. Serum IgA induced interleukin (IL)-6 and IL-8 production at both mRNA and protein levels, and enhanced cell proliferation and migration by the BSMCs. The synthetic phenotype markers were regulated and the contractile phenotype markers were downregulated by serum IgA. Mitogen-activated protein kinase, phosphatidylinositol 3-kinase/Akt, and nuclear factor-κB pathways were involved in IgA-induced IL-6 and IL-8 production. The BSMCs expressed transferrin receptor (TfR), and TfR siRNA transfection inhibited IL-6 and IL-8 production by serum IgA. In summary, serum IgA is a potent activator of the BSMCs at least partially via TfR.
Collapse
Affiliation(s)
- Sahoko Imoto
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan; Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
| | - Maho Suzukawa
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan.
| | - Kazufumi Takada
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan; Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
| | - Shizuka Watanabe
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan; Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
| | - Sayaka Igarashi
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan
| | - Masashi Kitani
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan
| | - Takahide Nagase
- Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
| | - Ken Ohta
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-City, Tokyo 204-8585, Japan; Japan Anti-Tuberculosis Association, JATA Fukujuji Hospital, 3-1-24 Matsuyama, Kiyose-City, Tokyo 204-8522, Japan.
| |
Collapse
|
7
|
Imoto S, Suzukawa M, Takeda K, Motohashi T, Nagase M, Enomoto Y, Kawasaki Y, Nakano E, Watanabe M, Shimada M, Takada K, Watanabe S, Nagase T, Ohta K, Teruya K, Nagai H. Evaluation of tuberculosis diagnostic biomarkers in immunocompromised hosts based on cytokine levels in QuantiFERON-TB Gold Plus. Tuberculosis (Edinb) 2022; 136:102242. [PMID: 35944309 DOI: 10.1016/j.tube.2022.102242] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2022] [Revised: 07/11/2022] [Accepted: 07/26/2022] [Indexed: 11/19/2022]
Abstract
Tuberculosis (TB) remains a serious health concern globally. QuantiFERON-TB (QFT) is a diagnostic tool for TB detection, and its sensitivity is reduced in immunocompromised hosts with low T lymphocyte counts or abnormal T cell function. This study aimed to evaluate the correlation between T cell and cytokine levels in patients with active TB using QFT-Plus. Forty-five patients with active TB were enrolled, and the cytokines in QFT-Plus tube supernatants were quantified using the MAGPIX System. CD4+ T cell count negatively correlated with patient age (p < 0.001, r = -0.51). The levels of TB1-responsive interleukin-1 receptor antagonist (IL-1Ra) and IL-2 correlated with CD4+ T cell count, whereas the levels of TB2-responsive IL-1Ra and IFN-γ-induced protein 10 correlated with both CD4+ and CD8+ T cell counts. Cytokines that correlated with CD4+ and CD8+ T cell counts might not be suitable TB diagnostic biomarkers in immunocompromised hosts. Notably, cytokines that did not correlate with the T cell counts, such as monocyte chemoattractant protein-1, might be candidate biomarkers for TB in immunocompromised hosts. Our findings might help improve TB diagnosis, which could enable prompt treatment and minimize poor disease outcomes.
Collapse
Affiliation(s)
- Sahoko Imoto
- National Hospital Organization Tokyo National Hospital, Tokyo, 204-8585, Japan; Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8655, Japan
| | - Maho Suzukawa
- National Hospital Organization Tokyo National Hospital, Tokyo, 204-8585, Japan.
| | - Keita Takeda
- National Hospital Organization Tokyo National Hospital, Tokyo, 204-8585, Japan
| | - Takumi Motohashi
- National Hospital Organization Tokyo National Hospital, Tokyo, 204-8585, Japan
| | - Maki Nagase
- National Hospital Organization Tokyo National Hospital, Tokyo, 204-8585, Japan
| | - Yu Enomoto
- National Hospital Organization Tokyo National Hospital, Tokyo, 204-8585, Japan
| | - Yuichiro Kawasaki
- National Hospital Organization Tokyo National Hospital, Tokyo, 204-8585, Japan
| | - Eri Nakano
- National Hospital Organization Tokyo National Hospital, Tokyo, 204-8585, Japan
| | - Masato Watanabe
- National Hospital Organization Tokyo National Hospital, Tokyo, 204-8585, Japan
| | - Masahiro Shimada
- National Hospital Organization Tokyo National Hospital, Tokyo, 204-8585, Japan
| | - Kazufumi Takada
- National Hospital Organization Tokyo National Hospital, Tokyo, 204-8585, Japan; Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Shizuka Watanabe
- National Hospital Organization Tokyo National Hospital, Tokyo, 204-8585, Japan; Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8655, Japan
| | - Takahide Nagase
- Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8655, Japan
| | - Ken Ohta
- National Hospital Organization Tokyo National Hospital, Tokyo, 204-8585, Japan; Japan Anti-Tuberculosis Association, Fukujuji Hospital, Tokyo, 193-0834, Japan
| | - Katsuji Teruya
- National Center for Global Health and Medicine, Tokyo, 162-8655, Japan
| | - Hideaki Nagai
- National Hospital Organization Tokyo National Hospital, Tokyo, 204-8585, Japan
| |
Collapse
|
8
|
Watanabe S, Kobayashi K, Suzukawa M, Igarashi S, Takada K, Imoto S, Kitani M, Fukami T, Nagase T, Ohta K. Identification of ANXA2 on epithelial cells as a new receptor for secretory IgA using immunoprecipitation and mass spectrometry. Clin Exp Immunol 2022; 208:351-360. [PMID: 35511485 PMCID: PMC9226145 DOI: 10.1093/cei/uxac043] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Revised: 03/29/2022] [Accepted: 04/29/2022] [Indexed: 11/15/2022] Open
Abstract
Secretory immunoglobulin A plays an important role in the protection against exogenous pathogens and antigens, but it has also been reported to have pathogenic potential. We previously found that secretory immunoglobulin A accumulated in the peripheral lungs during idiopathic pulmonary fibrosis and that transferrin receptor/CD71 was partially involved in secretory immunoglobulin A-induced inflammatory cytokine production in A549 cells. This study aimed to identify the receptor responsible for the induction of cytokine production by secretory immunoglobulin A-stimulated airway epithelial cells. To this end, immunoprecipitation followed by time-of-flight mass spectrometry and peptide mass fingerprinting were performed and Annexin A2 was detected as a novel receptor for secretory immunoglobulin A. Enzyme-linked immunosorbent assay demonstrated binding of secretory immunoglobulin A to Annexin A2, and flow cytometry showed robust expression of Annexin A2 on the surface of BEAS-2B cells, A549 cells, and normal human bronchial/tracheal epithelial cells. Experiments in A549 cells using Annexin A2 small interfering RNA and neutralizing antibodies suggested that Annexin A2 was partially involved in the production of interleukin-8/CXCL8 and C-C motif chemokine ligand 2/monocyte chemoattractant protein-1 induced by secretory immunoglobulin A. Immunohistochemistry using lung sections revealed clear expression of Annexin A2 on airway epithelial cells, although the staining remained equivalent in idiopathic pulmonary fibrosis, asthma, and healthy control lungs. In conclusion, we identified that Annexin A2 expressed in airway epithelial cells is a novel receptor for secretory immunoglobulin A, which is involved in cytokine synthesis.
Collapse
Affiliation(s)
- Shizuka Watanabe
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.,Department of Respiratory Medicine, University of Tokyo, Tokyo, Japan
| | - Koichi Kobayashi
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.,Department of Respiratory Medicine, University of Tokyo, Tokyo, Japan.,Department of Internal medicine, Yoshikawa Central General Hospital, Saitama, Japan
| | - Maho Suzukawa
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Sayaka Igarashi
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Kazufumi Takada
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.,Department of Geriatric Medicine, University of Tokyo, Tokyo, Japan
| | - Sahoko Imoto
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.,Department of Respiratory Medicine, University of Tokyo, Tokyo, Japan
| | - Masashi Kitani
- Department of Pathology, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Takeshi Fukami
- Department of Surgery, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Takahide Nagase
- Department of Respiratory Medicine, University of Tokyo, Tokyo, Japan
| | - Ken Ohta
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.,Japan Anti-Tuberculosis Association (JATA), Fukujuji Hospital, Tokyo, Japan
| |
Collapse
|
9
|
Imoto S, Suzukawa M, Takeda K, Asari I, Watanabe S, Tohma S, Nagase T, Ohta K, Teruya K, Nagai H. Evaluation of cytokine levels in response to mitogen among HIV-1-infected blood cells and their relationships to the number of T cells. Cytokine 2022; 153:155840. [PMID: 35276635 DOI: 10.1016/j.cyto.2022.155840] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Revised: 02/18/2022] [Accepted: 02/21/2022] [Indexed: 01/01/2023]
Abstract
BACKGROUND Human immunodeficiency virus-1 (HIV-1) infection causes loss and anergy of CD4+ and CD8+ T cells, leading to opportunistic infections, including tuberculosis (TB). QuantiFERON®-TB (QFT) is used as a diagnostic tool to detect TB, but it exhibits limited accuracy among subjects with low CD4+ T cell numbers, including HIV-1-infected individuals. The present study aimed to determine the effect of HIV-1 infection and patients' blood T cell numbers on cytokine production in response to mitogen (Mit) stimulation. METHODS The number of CD4+ and CD8+ T cells in HIV-1-infected individuals was quantified. Levels of various cytokines in Mit-stimulated and un-stimulated (Nil) supernatants of QFT gold "in tube" were assessed using a MAGPIX System. The correlation between cytokine levels and CD4+/CD8+ T cell counts in response to Mit was analyzed. The cytokine levels were compared between HIV-1-infected and healthy subjects. RESULTS HIV-1-infected individuals (110) and control subjects (27) were enrolled. Interferon (IFN)-γ, interleukin-1 receptor antagonist (IL-1RA), IL-6, IL-8, and regulated on activation, normal T cell expressed and secreted (RANTES) values in Mit-Nil tubes showed a significant correlation with CD4+ T cell counts, while IFN-γ, IL-6, and IFN-γ-induced protein 10 (IP-10) values in Mit-Nil tubes had significant correlation with CD8+ T cell counts. IL-1RA, IL-8, IP-10, platelet-derived growth factor (PDGF)-BB, and RANTES levels in Nil tubes were significantly higher in the HIV-1-infected group. IFN-γ, IL-2, IL-5, IL-6, IP-10, and macrophage inflammatory protein-1β values in Mit-Nil tubes were significantly higher, and PDGF-BB and RANTES levels were significantly lower in the HIV-1-infected group. CONCLUSION The functions of HIV-1-infected T cells and uninfected T cells, such as spontaneous and responsive cytokine production in response to Mit, were different. Our findings may be useful for developing new clinical tools for patients with low T cell counts. Additionally, the study provides new insights into the pathogenesis of HIV-1 infection.
Collapse
Affiliation(s)
- Sahoko Imoto
- National Hospital Organization Tokyo National Hospital, Tokyo 204-8585, Japan; Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
| | - Maho Suzukawa
- National Hospital Organization Tokyo National Hospital, Tokyo 204-8585, Japan.
| | - Keita Takeda
- National Hospital Organization Tokyo National Hospital, Tokyo 204-8585, Japan
| | - Isao Asari
- National Hospital Organization Tokyo National Hospital, Tokyo 204-8585, Japan
| | - Shizuka Watanabe
- National Hospital Organization Tokyo National Hospital, Tokyo 204-8585, Japan; Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
| | - Shigeto Tohma
- National Hospital Organization Tokyo National Hospital, Tokyo 204-8585, Japan
| | - Takahide Nagase
- Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan
| | - Ken Ohta
- National Hospital Organization Tokyo National Hospital, Tokyo 204-8585, Japan; Japan Anti-Tuberculosis Association, Fukujuji Hospital, Tokyo 193-0834, Japan
| | - Katsuji Teruya
- National Center for Global Health and Medicine, Tokyo 162-8655, Japan
| | - Hideaki Nagai
- National Hospital Organization Tokyo National Hospital, Tokyo 204-8585, Japan
| |
Collapse
|
10
|
Abstract
During the COVID-19 pandemic, it has been important to both minimize the risk of infection and restore daily life. As a typical example, mass gathering events, such as sporting events, are gradually becoming more common, thanks to the measures taken to contain COVID-19. Some pilot studies have been launched at governments' initiative to investigate the risk of infection without measures such as face masks and physical distancing at mass gathering events, but the ethics of these studies should be carefully considered. On the other hand, it is still beneficial to implement infection control measures at mass gathering events and, in parallel, to estimate the risk of infection with measures in place, especially under a lack of vaccination progress or the spread of mutant strains possibly resistant to vaccines. To help improve compliance with measures taken by spectators and organizers and to ensure their effectiveness, we have conducted quantitative evaluations of the implementation of such measures by monitoring CO2 concentrations, assessing the proportion of people wearing face masks and analysing human flow at the event. This approach allows us to share our observations with stakeholders and participants, enabling us to protect the culture of mass gathering events, minimize the risk of infection and restore a sense of well-being in daily life.
Collapse
Affiliation(s)
- M Murakami
- Department of Health Risk Communication, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, Fukushima 960-1295, Japan
| | - T Yasutaka
- Institute for Geo-Resources and Environment, National Institute of Advanced Industrial Science and Technology (AIST), 1-1-1, Higashi, Tsukuba, Ibaraki 305-8567, Japan
| | - M Onishi
- Artificial Intelligence Research Center, National Institute of Advanced Industrial Science and Technology (AIST), 2-4-7 Aomi, Koto-ku, Tokyo 135-0064, Japan
| | - W Naito
- Research Institute of Science for Safety and Sustainability, National Institute of Advanced Industrial Science and Technology (AIST), 16-1, Onogawa, Tsukuba, Ibaraki 305-8569, Japan
| | - N Shinohara
- Research Institute of Science for Safety and Sustainability, National Institute of Advanced Industrial Science and Technology (AIST), 16-1, Onogawa, Tsukuba, Ibaraki 305-8569, Japan
| | - T Okuda
- Department of Applied Chemistry, Faculty of Science and Technology, Keio University, 3-14-1 Hiyoshi, Kohoku, Yokohama, Kanagawa 223-8522, Japan
| | - K Fujii
- R&D-Hygiene Science Research Center, Kao Corporation, 2-1-3, Bunka, Sumida-ku, Tokyo 131-8501, Japan
| | - K Katayama
- Laboratory of Sequence Analysis, Human Genome Center, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
| | - S Imoto
- Division of Health Medical Intelligence, Human Genome Center, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
| |
Collapse
|
11
|
Saiki R, Momozawa Y, Nannya Y, Nakagawa M, Ochi Y, Yoshizato T, Terao C, Kuroda Y, Shiraishi Y, Chiba K, Tanaka H, Niida A, Imoto S, Matsuda K, Morisaki T, Murakami Y, Kamatani Y, Matsuda S, Kubo M, Miyano S, Makishima H, Ogawa S. Topic: AS04-MDS Biology and Pathogenesis/AS04a-Normal, MDS, and leukemic stem cells. Leuk Res 2021. [DOI: 10.1016/j.leukres.2021.106679.3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
12
|
Kawaguchi K, Masuda N, Tanaka S, Bando H, Nishimura T, Kadoya T, Yamanaka T, Imoto S, Velaga R, Tamura N, Aruga T, Maeshima Y, Takada M, Suzuki E, Ueno T, Ogawa S, Haga H, Ohno S, Morita S, Toi M. 1766P Longitudinal alteration of cytokine profile in the peripheral blood and clinical response for neoadjuvant chemotherapy in triple-negative breast cancer patients (translational research of the JBCRG-22 trial). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
13
|
Watanabe S, Suzukawa M, Tashimo H, Ohshima N, Asari I, Imoto S, Kobayashi N, Tohma S, Nagase T, Ohta K. High serum cytokine levels may predict the responsiveness of patients with severe asthma to benralizumab. J Asthma 2021; 59:1604-1612. [PMID: 34121592 DOI: 10.1080/02770903.2021.1942039] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
OBJECTIVE Benralizumab, a humanized monoclonal antibody against human IL-5 receptor alpha, is effective in treating eosinophilic severe asthma. However, patients' response to benralizumab varies widely. In this study, we aimed to identify a new serum biomarker to accurately predict benralizumab response. METHODS Seventeen benralizumab-treated patients with severe eosinophilic asthma were enrolled. Blood samples were collected; pulmonary function tests were performed and questionnaires were disseminated at baseline and after 1, 2, 4, and 6 months of treatment. Blood cytokine levels were measured. Response was defined as an elevation in forced expiratory volume in 1 s of at least 10.4% from baseline after 4 months of treatment. RESULTS There were nine respondents and eight non-respondents. The non-responders showed significantly higher baseline serum interferon-γ; interleukin (IL)-4, -5, -6, -7, and -12p70; IL-17/IL-17A; IL-17E/IL-25; IL-18/IL-1F4; chemokine (C-C motif) ligand (CCL)3/macrophage inflammatory protein (MIP)-1α; CCL4/MIP-1β; CCL11/eotaxin; matrix metalloproteinase-12; tumor necrosis factor-α, and thymic stromal lymphopoietin levels. After benralizumab administration, the serum CCL3/MIP-1α and CCL11/eotaxin levels significantly and persistently increased in the responders (CCL3/MIP-1α, responders: 144.5 ± 37.9 pg/ml (baseline) vs. 210.3 ± 59.4 pg/ml (4 months), p = 0.009; non-responders: 270.8 ± 139.8 pg/ml (baseline) vs. 299.5 ± 159.9 pg/ml (4 months), p = 0.33; CCL11/eotaxin, responders: 167.9 ± 62.6 pg/ml (baseline) vs. 326.7 ± 134.4 pg/ml (4 months), p = 0.038; non-responders: 420.9 ± 323.1 pg/ml (baseline) vs. 502.1 ± 406.0 pg/ml (4 months), p = 0.30). CONCLUSION Low baseline serum inflammatory cytokine levels may be useful in predicting a good benralizumab response.Supplemental data for this article is available online at at www.tandfonline.com/ijas .
Collapse
Affiliation(s)
- Shizuka Watanabe
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.,Department of Respiratory Medicine, University of Tokyo, Tokyo, Japan
| | - Maho Suzukawa
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.,Asthma, Allergy and Rheumatology Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Hiroyuki Tashimo
- Asthma, Allergy and Rheumatology Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Nobuharu Ohshima
- Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Isao Asari
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Sahoko Imoto
- Clinical Research Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.,Department of Respiratory Medicine, University of Tokyo, Tokyo, Japan
| | - Nobuyuki Kobayashi
- Asthma, Allergy and Rheumatology Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Shigeto Tohma
- Asthma, Allergy and Rheumatology Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan
| | - Takahide Nagase
- Department of Respiratory Medicine, University of Tokyo, Tokyo, Japan
| | - Ken Ohta
- Asthma, Allergy and Rheumatology Center, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.,Department of Respiratory Medicine, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
| |
Collapse
|
14
|
Imoto S, Satomi R, Watase M, So M, Murakami H, Hosoo S, Miwa I, Fujimoto K, Nukaga S, Yagi K, Oguro S, Oyama T, Kato R, Oyamada Y. An Adult Case of Pulmonary Artery Sling Accompanied by Tracheobronchomalacia. Intern Med 2019; 58:1621-1624. [PMID: 30713315 PMCID: PMC6599931 DOI: 10.2169/internalmedicine.2089-18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Pulmonary artery (PA) sling is a congenital disease in which the left PA abnormally arises from the right PA and is usually diagnosed during the infantile period. We present an adult case of PA sling accompanied by tracheobronchomalacia found in a 49-year-old woman with a history of recurrent pneumonia. Computed tomography of the chest showed that the left lung was nourished by two aberrant PAs. Bronchoscopy demonstrated achondroplasia of the trachea and the right bronchus, which we speculate to have resulted in their stenosis. The recurrent pneumonia was attributable to these tracheobronchial structural abnormalities; we therefore stress the importance of focusing on the anatomic abnormalities in such cases.
Collapse
Affiliation(s)
- Sahoko Imoto
- Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Japan
| | - Ryosuke Satomi
- Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Japan
| | - Mayuko Watase
- Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Japan
| | - Matsuo So
- Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Japan
| | - Hiroaki Murakami
- Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Japan
| | - Sakiko Hosoo
- Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Japan
| | - Iio Miwa
- Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Japan
| | - Kazuyuki Fujimoto
- Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Japan
| | - Shigenari Nukaga
- Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Japan
| | - Kazuma Yagi
- Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Japan
| | - Sota Oguro
- Department of Radiology, National Hospital Organization Tokyo Medical Center, Japan
| | - Takahiko Oyama
- Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Japan
| | - Ryoichi Kato
- Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Japan
| | - Yoshitaka Oyamada
- Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Japan
| |
Collapse
|
15
|
Matsumoto K, Futamura M, Miyaki T, Iwasa T, Imoto S, Doi M, Tokunaga S, Aogi K, Yoshimura K, Takano T. A phase 2 study evaluating dose dense AC (ddAC) followed by dose dense paclitaxel (ddP) supported by 3.6 mg peg-filgrastim (ddAC-ddP3.6) for patients (pts) with primary breast cancer (PBC) in Japan -WJOG9016B-. Breast 2019. [DOI: 10.1016/s0960-9776(19)30103-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
16
|
Imoto S, Futamura M, Toi M, Fujiwara Y, Ueno T, Im YH, Im SA, Ahn SG, Lee JE, Park YH, Wang K, Kitagawa Y, Nishiyama M. Abstract OT2-05-02: International retrospective cohort study of locoregional and systemic therapy in oligometastatic breast cancer (OLIGO-BC1). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot2-05-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Breast cancer (BC) is so-called “systemic disease”, because disseminated cancer cells in bone marrow and blood are detected even in early BC patients. Despite adjuvant therapy and postoperative radiation therapy, patients with triple negative BC and Luminal B-like BC often relapse early and systemic therapy is the only way to control disease progression. On the other hand, some BC patients relapse several years later. In such patients, oligometastases are occasionally diagnosed, because metastatic cancer cells are slowly growing and indolent. Oligometastatic BC is defined as low volume metastatic disease with limited number and size of metastatic lesions (up to five and not necessarily in the same organ). This definition is proposed in the Advanced Breast Cancer guidelines that are developed as a joint effort from European School of Oncology and European Society of Medical Oncology. Several retrospective studies demonstrated survival benefit of locoregional therapy in addition to systemic therapy. Locoregional therapy consisted of surgical resection, radiation therapy, ablation therapy, etc. However, it remains unclear about survival benefit of combined therapy in oligometastatic BC. To improve the standard of cancer treatment through the cooperate studies on more effective therapeutic strategies based on drugs, surgery and/or radiotherapy, Federation of Asian Clinical Oncology (FACO) was established in 2012 by Chinese Society of Clinical Oncology (CSCO), Korean Society of Medical Oncology (KSMO) and Japan Society of Clinical Oncology (JSCO). Thus, FACO conducted a retrospective cohort study on oligometastatic BC. The primary endpoint is to compare the estimated 5-year overall survival (OS) of oligometastatic BC patients treated with combined therapy and systemic therapy alone. To hypothesize that combined therapy has more advantage of OS in oligometastatic BC, the 5-year OS rates are expected to be 50% and 40%, respectively. The estimated sample size is calculated to be the number of 698 cases (349 cases in each group) needed to prove the superiority of survival with a two-sided type I error rate of 5% and a statistical power of 80%. Case registry opened in February 2018 and will close in January 2019. We planned to register 700 cases, i.e., 234 cases each from investigators of CSCO, KSMO and JSCO. Update information will be discussed.
Citation Format: Imoto S, Futamura M, Toi M, Fujiwara Y, Ueno T, Im Y-H, Im S-A, Ahn SG, Lee JE, Park YH, Wang K, Kitagawa Y, Nishiyama M. International retrospective cohort study of locoregional and systemic therapy in oligometastatic breast cancer (OLIGO-BC1) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT2-05-02.
Collapse
Affiliation(s)
- S Imoto
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - M Futamura
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - M Toi
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Y Fujiwara
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - T Ueno
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Y-H Im
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - S-A Im
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - SG Ahn
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - JE Lee
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - YH Park
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - K Wang
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Y Kitagawa
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - M Nishiyama
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| |
Collapse
|
17
|
Iida Y, Yamauchi T, Yamazaki T, Ito T, Kawamura M, Okawa M, Imoto S. Effects of neuromuscular electrical stimulation and branched chain amino acid intake on recovery of muscle strength in sarcopenia patients undergoing cardiac surgery. Clin Nutr 2018. [DOI: 10.1016/j.clnu.2018.06.1148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Imoto S, Saito Oba M, Masuda N, Nagashima T, Wada N, Takashima T, Kitada M, Kawada M, Hayashida T, Taguchi T, Aihara T, Miura D, Toh U, Yoshida M, Sugae S, Yoneyama K, Matsumoto H, Jinno H, Sakamoto J. Abstract OT2-01-01: Observational study of axilla treatment for breast cancer patients with 1 to 3 positive micrometastases or macrometastases in sentinel lymph nodes. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot2-01-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
[Background] Axilla surgery in node-positive breast cancer is dramatically changing from axillary lymph node dissection (ALND) to sentinel node biopsy (SNB). From the results of ACOSOG Z0011, IBCSG23-01 and AMAROS trials, adjuvant therapy and regional node irradiation could reduce regional lymph node recurrence for sentinel node-positive breast cancer patients. However, optimal indication of SNB alone remains uncertain. Trial design: To evaluate the outcome of sentinel node-positive breast cancer patients, the Japanese Society for Sentinel Node Navigation Surgery (SNNS) conducted a prospective cohort study in 2013 (UMIN000011782, Jpn J Clin Oncol, p.876-9, 2014). [Eligibility criteria] For eligible patients, SNB was performed or scheduled after 1 January 2012. Then 1 to 3 positive micrometastases or macrometastases in sentinel lymph nodes are confirmed by histological or molecular diagnosis. Primary chemotherapy before or after SNB is also acceptable for registration. [Specific aims] The primary endpoint is the 5-year recurrence rate of regional lymph node in patients treated with SNB alone. The secondary endpoint is the 5-year overall survival rate of this cohort. Patients treated with SNB followed by ALND are also registered simultaneously to compare the prognosis. The propensity score matching (PSM) is used to make the distributions of baseline risk factors comparable. [Statistical method] Based on an estimated recurrence rate of 5% at 5 years among patients treated with SNB alone, 240 patients are needed to give a 80% power to reject the null hypothesis that the recurrence rate is 10% with a one-sided type I error rate of 2.5%. If we consider that some patients will be lost to follow-up or become ineligible, a total of 250 patients will be needed to comprise the sample. [Present accrual] Eight hundred and eighty patients who underwent SNB alone or SNB followed by ALND were registered from 27 participating institutes between 2013 and 2016. Data cleaning is being performed. Patient's background and PSM will be reported.
Citation Format: Imoto S, Saito Oba M, Masuda N, Nagashima T, Wada N, Takashima T, Kitada M, Kawada M, Hayashida T, Taguchi T, Aihara T, Miura D, Toh U, Yoshida M, Sugae S, Yoneyama K, Matsumoto H, Jinno H, Sakamoto J. Observational study of axilla treatment for breast cancer patients with 1 to 3 positive micrometastases or macrometastases in sentinel lymph nodes [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT2-01-01.
Collapse
Affiliation(s)
- S Imoto
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| | - M Saito Oba
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| | - N Masuda
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| | - T Nagashima
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| | - N Wada
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| | - T Takashima
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| | - M Kitada
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| | - M Kawada
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| | - T Hayashida
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| | - T Taguchi
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| | - T Aihara
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| | - D Miura
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| | - U Toh
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| | - M Yoshida
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| | - S Sugae
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| | - K Yoneyama
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| | - H Matsumoto
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| | - H Jinno
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| | - J Sakamoto
- Kyorin University School of Medicine, Mitaka, Japan; Toho University; National Hospital Organization Osaka National Hospital; Chiba University Graduate School of Medicine; Tokyo Dental College Ichikawa General Hospital; Osaka City University Graduate School of Medicine; Asahikawa Medical University; KKR Sapporo Medical Center; Keio University School of Medicine; Kyoto Prefectural University of Medicine; Breast Center, Aihara Hospital; Toranomon Hospital; Kurume University School of Medicine; Seirei Hamamatsu General Hospital; Yokohama City University Graduate School of Medicine; Hiratsuka City Hospita; Saitama Cancer Center; Teikyo University School of Medicine; Tokai Central Hospital
| |
Collapse
|
19
|
Imoto S, Ueno T, Isaka H, Ito H, Miyamoto K, Kitamura M. 228. Phase II study on radiofrequency ablation in early breast cancer. Eur J Surg Oncol 2016. [DOI: 10.1016/j.ejso.2016.06.160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
20
|
Mao Y, Tamura T, Yuki Y, Abe D, Tamada Y, Imoto S, Tanaka H, Homma H, Tagawa K, Miyano S, Okazawa H. The hnRNP-Htt axis regulates necrotic cell death induced by transcriptional repression through impaired RNA splicing. Cell Death Dis 2016; 7:e2207. [PMID: 27124581 PMCID: PMC4855646 DOI: 10.1038/cddis.2016.101] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2016] [Revised: 03/18/2016] [Accepted: 03/21/2016] [Indexed: 12/12/2022]
Abstract
In this study, we identify signaling network of necrotic cell death induced by transcriptional repression (TRIAD) by α-amanitin (AMA), the selective RNA polymerase II inhibitor, as a model of neurodegenerative cell death. We performed genetic screen of a knockdown (KD) fly library by measuring the ratio of transformation from pupa to larva (PL ratio) under TRIAD, and selected the cell death-promoting genes. Systems biology analysis of the positive genes mapped on protein-protein interaction databases predicted the signaling network of TRIAD and the core pathway including heterogeneous nuclear ribonucleoproteins (hnRNPs) and huntingtin (Htt). RNA sequencing revealed that AMA impaired transcription and RNA splicing of Htt, which is known as an endoplasmic reticulum (ER)-stabilizing molecule. The impairment in RNA splicing and PL ratio was rescued by overexpresion of hnRNP that had been also affected by transcriptional repression. Fly genetics with suppressor or expresser of Htt and hnRNP worsened or ameliorated the decreased PL ratio by AMA, respectively. Collectively, these results suggested involvement of RNA splicing and a regulatory role of the hnRNP-Htt axis in the process of the transcriptional repression-induced necrosis.
Collapse
Affiliation(s)
- Y Mao
- Department of Neuropathology, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
| | - T Tamura
- Department of Neuropathology, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
| | - Y Yuki
- Department of Neuropathology, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
| | - D Abe
- Department of Neuropathology, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
| | - Y Tamada
- Department of Computer Science, Graduate School of Information Science and Technology, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
| | - S Imoto
- Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan
| | - H Tanaka
- Department of Neuropathology, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
| | - H Homma
- Department of Neuropathology, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
| | - K Tagawa
- Department of Neuropathology, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
| | - S Miyano
- Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan
| | - H Okazawa
- Department of Neuropathology, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
- Center for Brain Integration Research, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan
| |
Collapse
|
21
|
Takeda A, Yamase Y, Koike W, Hayashi S, Imoto S, Nakamura H. Pulmonary thromboembolism as a result of ovarian vein thrombosis after laparoscopic-assisted vaginal hysterectomy for uterine myoma. J Obstet Gynaecol Res 2016; 42:743-747. [DOI: 10.1111/jog.12973] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2015] [Revised: 12/23/2015] [Accepted: 01/10/2016] [Indexed: 11/28/2022]
Affiliation(s)
- A. Takeda
- Department of Obstetrics and Gynecology; Gifu Prefectural Tajimi Hospital; Tajimi Gifu Japan
| | - Y. Yamase
- Department of Cardiovascular Medicine; Gifu Prefectural Tajimi Hospital; Tajimi Gifu Japan
| | - W. Koike
- Department of Diagnostic Radiology; Gifu Prefectural Tajimi Hospital; Tajimi Gifu Japan
| | - S. Hayashi
- Department of Obstetrics and Gynecology; Gifu Prefectural Tajimi Hospital; Tajimi Gifu Japan
| | - S. Imoto
- Department of Obstetrics and Gynecology; Gifu Prefectural Tajimi Hospital; Tajimi Gifu Japan
| | - H. Nakamura
- Department of Obstetrics and Gynecology; Gifu Prefectural Tajimi Hospital; Tajimi Gifu Japan
| |
Collapse
|
22
|
Takahashi M, Ito T, Oura S, Nagamine S, Yamamoto N, Yamamichi N, Earashi M, Doihara H, Imoto S, Mitsuyama S, Akazawa K. Abstract P3-13-07: Radiofrequency ablation (RFA) is a promising treatment option for primary breast cancer: Experience in 386 Japanese breast cancer patients. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-13-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. Radiofrequency ablation (RFA) is used for the treatment of various solid tumors. Several small experiences have reported as a primary treatment for breast cancer using RFA. However, the clinical benefits remain uncertain. We retrospectively studied 386 patients and analyzed their RFA-related complications and outcomes.
Methods. A clinical database was constructed from 10 institutions. RFA was performed using an electrical generator connected to a single cooled-tip electrode or multiple electrodes. Adjuvant systemic therapy and whole breast radiation were administered according to the clinicopathological background of each patient. Follow-up periods ranged from 1 to 90 months (mean 45.4 months). RFA-related complications and risk factors for in-breast recurrence after RFA were evaluated. Variables evaluated included patient characteristics, pre- and post-operative imaging modalities, tissue sampling modalities, and RFA-related factors.
Results. Skin burns were observed in 7 patients (1.8 %) and RFA-induced damage to the nipple-areolar complex in 7 patients (1.8 %). Persistent induration of the breast after RFA was observed in 137 patients (35.5 %). Eleven patients (2.8 %) developed in-breast recurrence. In-breast recurrence was more frequent in patients with tumor size >2.0 cm, ER-negative tumor, HER2-positive tumor, positive nodes, no breast irradiation and adjuvant chemotherapy.
Conclusions. Skin burns were a major problem after RFA, but the frequency of burns was relatively low. Breast induration was also developed, but it did not bring harmful effect to the patients with this complication. We conclude that RFA is a promising treatment option for solid T1 breast cancer without malignant potential.
Citation Format: Takahashi M, Ito T, Oura S, Nagamine S, Yamamoto N, Yamamichi N, Earashi M, Doihara H, Imoto S, Mitsuyama S, Akazawa K. Radiofrequency ablation (RFA) is a promising treatment option for primary breast cancer: Experience in 386 Japanese breast cancer patients. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-13-07.
Collapse
Affiliation(s)
- M Takahashi
- NHO Hokkaido Cancer Center, Sapporo, Japan; Division of Surgery, Rinku General Medical Center; Division of Breast Surgical Oncology, Wakayama Medical University; Division of Surgery, Okinawa Red Cross Hospita; Division of Breast Surgery, Chiba Cancer Center; Fukui Kousei Hospital; Division of Breast Surgery, Yao General Hospital; Breast and Endocrine Surgery, Okayama University Hospital; Kyorin University School of Medicine; Kitakyushu Municipal Medical Center; Niigata University Medical and Dental Hospital
| | - T Ito
- NHO Hokkaido Cancer Center, Sapporo, Japan; Division of Surgery, Rinku General Medical Center; Division of Breast Surgical Oncology, Wakayama Medical University; Division of Surgery, Okinawa Red Cross Hospita; Division of Breast Surgery, Chiba Cancer Center; Fukui Kousei Hospital; Division of Breast Surgery, Yao General Hospital; Breast and Endocrine Surgery, Okayama University Hospital; Kyorin University School of Medicine; Kitakyushu Municipal Medical Center; Niigata University Medical and Dental Hospital
| | - S Oura
- NHO Hokkaido Cancer Center, Sapporo, Japan; Division of Surgery, Rinku General Medical Center; Division of Breast Surgical Oncology, Wakayama Medical University; Division of Surgery, Okinawa Red Cross Hospita; Division of Breast Surgery, Chiba Cancer Center; Fukui Kousei Hospital; Division of Breast Surgery, Yao General Hospital; Breast and Endocrine Surgery, Okayama University Hospital; Kyorin University School of Medicine; Kitakyushu Municipal Medical Center; Niigata University Medical and Dental Hospital
| | - S Nagamine
- NHO Hokkaido Cancer Center, Sapporo, Japan; Division of Surgery, Rinku General Medical Center; Division of Breast Surgical Oncology, Wakayama Medical University; Division of Surgery, Okinawa Red Cross Hospita; Division of Breast Surgery, Chiba Cancer Center; Fukui Kousei Hospital; Division of Breast Surgery, Yao General Hospital; Breast and Endocrine Surgery, Okayama University Hospital; Kyorin University School of Medicine; Kitakyushu Municipal Medical Center; Niigata University Medical and Dental Hospital
| | - N Yamamoto
- NHO Hokkaido Cancer Center, Sapporo, Japan; Division of Surgery, Rinku General Medical Center; Division of Breast Surgical Oncology, Wakayama Medical University; Division of Surgery, Okinawa Red Cross Hospita; Division of Breast Surgery, Chiba Cancer Center; Fukui Kousei Hospital; Division of Breast Surgery, Yao General Hospital; Breast and Endocrine Surgery, Okayama University Hospital; Kyorin University School of Medicine; Kitakyushu Municipal Medical Center; Niigata University Medical and Dental Hospital
| | - N Yamamichi
- NHO Hokkaido Cancer Center, Sapporo, Japan; Division of Surgery, Rinku General Medical Center; Division of Breast Surgical Oncology, Wakayama Medical University; Division of Surgery, Okinawa Red Cross Hospita; Division of Breast Surgery, Chiba Cancer Center; Fukui Kousei Hospital; Division of Breast Surgery, Yao General Hospital; Breast and Endocrine Surgery, Okayama University Hospital; Kyorin University School of Medicine; Kitakyushu Municipal Medical Center; Niigata University Medical and Dental Hospital
| | - M Earashi
- NHO Hokkaido Cancer Center, Sapporo, Japan; Division of Surgery, Rinku General Medical Center; Division of Breast Surgical Oncology, Wakayama Medical University; Division of Surgery, Okinawa Red Cross Hospita; Division of Breast Surgery, Chiba Cancer Center; Fukui Kousei Hospital; Division of Breast Surgery, Yao General Hospital; Breast and Endocrine Surgery, Okayama University Hospital; Kyorin University School of Medicine; Kitakyushu Municipal Medical Center; Niigata University Medical and Dental Hospital
| | - H Doihara
- NHO Hokkaido Cancer Center, Sapporo, Japan; Division of Surgery, Rinku General Medical Center; Division of Breast Surgical Oncology, Wakayama Medical University; Division of Surgery, Okinawa Red Cross Hospita; Division of Breast Surgery, Chiba Cancer Center; Fukui Kousei Hospital; Division of Breast Surgery, Yao General Hospital; Breast and Endocrine Surgery, Okayama University Hospital; Kyorin University School of Medicine; Kitakyushu Municipal Medical Center; Niigata University Medical and Dental Hospital
| | - S Imoto
- NHO Hokkaido Cancer Center, Sapporo, Japan; Division of Surgery, Rinku General Medical Center; Division of Breast Surgical Oncology, Wakayama Medical University; Division of Surgery, Okinawa Red Cross Hospita; Division of Breast Surgery, Chiba Cancer Center; Fukui Kousei Hospital; Division of Breast Surgery, Yao General Hospital; Breast and Endocrine Surgery, Okayama University Hospital; Kyorin University School of Medicine; Kitakyushu Municipal Medical Center; Niigata University Medical and Dental Hospital
| | - S Mitsuyama
- NHO Hokkaido Cancer Center, Sapporo, Japan; Division of Surgery, Rinku General Medical Center; Division of Breast Surgical Oncology, Wakayama Medical University; Division of Surgery, Okinawa Red Cross Hospita; Division of Breast Surgery, Chiba Cancer Center; Fukui Kousei Hospital; Division of Breast Surgery, Yao General Hospital; Breast and Endocrine Surgery, Okayama University Hospital; Kyorin University School of Medicine; Kitakyushu Municipal Medical Center; Niigata University Medical and Dental Hospital
| | - K Akazawa
- NHO Hokkaido Cancer Center, Sapporo, Japan; Division of Surgery, Rinku General Medical Center; Division of Breast Surgical Oncology, Wakayama Medical University; Division of Surgery, Okinawa Red Cross Hospita; Division of Breast Surgery, Chiba Cancer Center; Fukui Kousei Hospital; Division of Breast Surgery, Yao General Hospital; Breast and Endocrine Surgery, Okayama University Hospital; Kyorin University School of Medicine; Kitakyushu Municipal Medical Center; Niigata University Medical and Dental Hospital
| |
Collapse
|
23
|
Yew PY, Alachkar H, Yamaguchi R, Kiyotani K, Fang H, Yap KL, Liu HT, Wickrema A, Artz A, van Besien K, Imoto S, Miyano S, Bishop MR, Stock W, Nakamura Y. Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2015; 50:1227-34. [PMID: 26052909 PMCID: PMC4559843 DOI: 10.1038/bmt.2015.133] [Citation(s) in RCA: 93] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2014] [Revised: 04/26/2015] [Accepted: 04/28/2015] [Indexed: 12/25/2022]
Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is one of curative treatment options for patients with hematologic malignancies. Although GVHD mediated by the donor's T lymphocytes remains the most challenging toxicity of allo-HSCT, graft-versus-leukemia (GVL) effect targeting leukemic cells, has an important role in affecting the overall outcome of patients with AML. Here we comprehensively characterized the TCR repertoire in patients who underwent matched donor or haplo-cord HSCT using next-generation sequencing approach. Our study defines the functional kinetics of each TCRA and TCRB clone, and changes in T-cell diversity (with identification of CDR3 sequences) and the extent of clonal expansion of certain T-cells. Using this approach, our study demonstrates that higher percentage of cord-blood cells at 30 days after transplant was correlated with higher diversity of TCR repertoire, implicating the role of cord-chimerism in enhancing immune recovery. Importantly, we found that GVHD and relapse, exclusive of each other, were correlated with lower TCR repertoire diversity and expansion of certain T-cell clones. Our results highlight novel insights into the balance between GVHD and GVL effect, suggesting that higher diversity early after transplant possibly implies lower risks of both GVHD and relapse following the HSCT transplantation.
Collapse
Affiliation(s)
- P Y Yew
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
| | - H Alachkar
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
| | - R Yamaguchi
- Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - K Kiyotani
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
| | - H Fang
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
| | - K L Yap
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
| | - H T Liu
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
| | - A Wickrema
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
| | - A Artz
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
| | - K van Besien
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
| | - S Imoto
- Health Intelligence Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - S Miyano
- Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.,Health Intelligence Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - M R Bishop
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
| | - W Stock
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
| | - Y Nakamura
- Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.,Department of Surgery, The University of Chicago, Chicago, IL, USA
| |
Collapse
|
24
|
Ito H, Shiwaku H, Yoshida C, Homma H, Luo H, Chen X, Fujita K, Musante L, Fischer U, Frints SGM, Romano C, Ikeuchi Y, Shimamura T, Imoto S, Miyano S, Muramatsu SI, Kawauchi T, Hoshino M, Sudol M, Arumughan A, Wanker EE, Rich T, Schwartz C, Matsuzaki F, Bonni A, Kalscheuer VM, Okazawa H. In utero gene therapy rescues microcephaly caused by Pqbp1-hypofunction in neural stem progenitor cells. Mol Psychiatry 2015; 20:459-71. [PMID: 25070536 PMCID: PMC4378255 DOI: 10.1038/mp.2014.69] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/19/2014] [Revised: 04/10/2014] [Accepted: 05/12/2014] [Indexed: 12/21/2022]
Abstract
Human mutations in PQBP1, a molecule involved in transcription and splicing, result in a reduced but architecturally normal brain. Examination of a conditional Pqbp1-knockout (cKO) mouse with microcephaly failed to reveal either abnormal centrosomes or mitotic spindles, increased neurogenesis from the neural stem progenitor cell (NSPC) pool or increased cell death in vivo. Instead, we observed an increase in the length of the cell cycle, particularly for the M phase in NSPCs. Corresponding to the developmental expression of Pqbp1, the stem cell pool in vivo was decreased at E10 and remained at a low level during neurogenesis (E15) in Pqbp1-cKO mice. The expression profiles of NSPCs derived from the cKO mouse revealed significant changes in gene groups that control the M phase, including anaphase-promoting complex genes, via aberrant transcription and RNA splicing. Exogenous Apc4, a hub protein in the network of affected genes, recovered the cell cycle, proliferation, and cell phenotypes of NSPCs caused by Pqbp1-cKO. These data reveal a mechanism of brain size control based on the simple reduction of the NSPC pool by cell cycle time elongation. Finally, we demonstrated that in utero gene therapy for Pqbp1-cKO mice by intraperitoneal injection of the PQBP1-AAV vector at E10 successfully rescued microcephaly with preserved cortical structures and improved behavioral abnormalities in Pqbp1-cKO mice, opening a new strategy for treating this intractable developmental disorder.
Collapse
Affiliation(s)
- H Ito
- Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, Tokyo, Japan
| | - H Shiwaku
- Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, Tokyo, Japan
| | - C Yoshida
- Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, Tokyo, Japan
| | - H Homma
- Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, Tokyo, Japan
| | - H Luo
- Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, Tokyo, Japan
| | - X Chen
- Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, Tokyo, Japan
| | - K Fujita
- Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, Tokyo, Japan
| | - L Musante
- Department of Human Molecular Genetics, Max-Planck Institute for Molecular Genetics, Berlin-Dahlem, Germany
| | - U Fischer
- Department of Human Molecular Genetics, Max-Planck Institute for Molecular Genetics, Berlin-Dahlem, Germany
| | - S G M Frints
- Department of Clinical Genetics, University Hospital azM Maastricht, Maastricht, The Netherlands,School for Oncology and Developmental Biology, GROW, Maastricht University, Maastricht, The Netherlands
| | - C Romano
- Unità Operativa Complessa di Pediatria e Genetica Medica, IRCCS Associazione Oasi Maria Santissima, Troina (Enna), Italy
| | - Y Ikeuchi
- Department of Anatomy and Neurobiology, Washington University School of Medicine, St Louis, MO, USA,Department of Neurobiology, Harvard Medical School, Boston, MA, USA
| | - T Shimamura
- Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - S Imoto
- Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - S Miyano
- Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - S-i Muramatsu
- Department of Neurology, Jichi Medical University, Tochigi, Japan
| | - T Kawauchi
- Department of Anatomy, Keio University School of Medicine, Tokyo, Japan
| | - M Hoshino
- Department of Biochemistry and Cellular Biology, National Center for Neurology and Psychiatry, Tokyo, Japan
| | - M Sudol
- Laboratory of Signal Transduction and Proteomic Profiling, Weis Center for Research, Geisinger Clinic, Danville, PA, USA
| | - A Arumughan
- Department of Neurogenetics, Max-Delbrück Center for Molecular Medicine, Berlin-Buch, Germany
| | - E E Wanker
- Department of Neurogenetics, Max-Delbrück Center for Molecular Medicine, Berlin-Buch, Germany
| | - T Rich
- Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
| | - C Schwartz
- JC Self Research Institute of Human Genetics, Greenwood Genetic Center, Greenwood, SC, USA
| | - F Matsuzaki
- Laboratory for Cell Asymmetry, Center for Developmental Biology, RIKEN, Chuo-ku, Kobe, Japan
| | - A Bonni
- Department of Anatomy and Neurobiology, Washington University School of Medicine, St Louis, MO, USA,Department of Neurobiology, Harvard Medical School, Boston, MA, USA
| | - V M Kalscheuer
- Department of Human Molecular Genetics, Max-Planck Institute for Molecular Genetics, Berlin-Dahlem, Germany
| | - H Okazawa
- Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, Tokyo, Japan,Department of Neuropathology, Medical Research Institute and Center for Brain Integration Research, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8510, Japan. E-mail:
| |
Collapse
|
25
|
Imoto S, Ueno T, Ito H, Imi K, Miyamoto K, Kitamura M. 145. Can radiofrequency ablation be an alternative to breast-conserving surgery in early breast cancer? Eur J Surg Oncol 2014. [DOI: 10.1016/j.ejso.2014.08.142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
26
|
Meretoja TJ, Audisio RA, Heikkilä PS, Bori R, Sejben I, Regitnig P, Luschin-Ebengreuth G, Zgajnar J, Perhavec A, Gazic B, Lázár G, Takács T, Kővári B, Saidan ZA, Nadeem RM, Castellano I, Sapino A, Bianchi S, Vezzosi V, Barranger E, Lousquy R, Arisio R, Foschini MP, Imoto S, Kamma H, Tvedskov TF, Jensen MB, Cserni G, Leidenius MHK. International multicenter tool to predict the risk of four or more tumor-positive axillary lymph nodes in breast cancer patients with sentinel node macrometastases. Breast Cancer Res Treat 2013; 138:817-27. [DOI: 10.1007/s10549-013-2468-3] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2013] [Accepted: 02/25/2013] [Indexed: 01/06/2023]
|
27
|
Imoto S, Osumi S, Aogi K, Hozumi Y, Mukai H, Iwata H, Yokota I, Yamaguchi T, Ohashi Y, Watanabe T, Takatsuka Y, Aihara T. Abstract P2-13-04: Superior efficacy of anastrozole to tamoxifen as adjuvant therapy for postmenopausal patients with hormone-responsive breast cancer. Efficacy results of long-term follow-up data from N-SAS BC 03 trial. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-13-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Aromatase inhibitors have been shown to be superior to tamoxifen as adjuvant therapy in postmenopausal patients with hormone-responsive breast cancer. Here we report the efficacy results of long-term follow-up data from N-SAS BC 03 trial (UMIN CTRID: C000000056), in which anastrozole was compared to tamoxifen in hormone-responsive postmenopausal early breast cancer patients who had taken tamoxifen for 1—4 years out of a total of 5 years of treatment as adjuvant therapy.
Patients and methods: Out of a total of 706 recruited patients, 696 patients (tamoxifen group, n=345; anastrozole group, n=351) were used as the full analysis set for the present study. The log-rank test was used to compare the two groups in terms of disease-free survival (DFS) and relapse-free survival (RFS), Kaplan-Meier estimates were calculated. The treatment effects were estimated by Cox's proportional hazard model and were expressed as hazard ratios, with associated 95% confidence intervals (CIs).
Results: After a median follow-up of 76.1 months, (range: 1.3–110 months), the unadjusted hazard ratio was 0.87 (95%Cl 0.60–1.26; log-rank p = 0.457) for DFS and 0.77 (95%Cl 0.49–1.22; log-rank p = 0.266) for RFS, both in favor of anastrozole. The estimated hazard ratio (95%CIs) for DFS and for RFS until each time point (right censored data) was as follows: until 30 months: 0.54 (0.30–0.98) and 0.48 (0.23–0.98), until 42 months; 0.65 (0.40–1.06) and 0.53 (0.29–0.97), until 54 months: 0.77 (0.50–1.19) and 0.63 (0.37–1.06), until 66 months: 0.82 (0.55–1.24) and 0.72 (0.44–1.17), until 78 months: 0.83 (0.57–1.23) and 0.73 (0.46–1.17), respectively. The hazard ratios (95%CIs) for DFS and for RFS until 36 months were 0.72 (95%Cl 0.43–1.22) and 0.58 (95%Cl 0.30–1.12), and those after 36 months were 1.06 (95%Cl 0.62–1.81) and 0.98 (95%Cl 0.51–1.88), respectively.
Conclusion: Superior efficacy of anastrozole to tamoxifen in the Japanese population was suggested over a long-term follow-up period. It was the greatest early after switching from tamoxifen and then decreased thereafter.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-13-04.
Collapse
Affiliation(s)
- S Imoto
- School of Medicine, Kyorin University, Tokyo, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan; Jichi Medical University, Tochigi, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Aichi, Japan; School of Public Health, University of Tokyo, Tokyo, Japan; Tohoku University School of Medicine, Miyagi, Japan; Hamamatsu Oncology Center, Shizuoka, Japan; Kansai Rosai Hospital, Hyogo, Japan; Aihara Hospital, Osaka, Japan
| | - S Osumi
- School of Medicine, Kyorin University, Tokyo, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan; Jichi Medical University, Tochigi, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Aichi, Japan; School of Public Health, University of Tokyo, Tokyo, Japan; Tohoku University School of Medicine, Miyagi, Japan; Hamamatsu Oncology Center, Shizuoka, Japan; Kansai Rosai Hospital, Hyogo, Japan; Aihara Hospital, Osaka, Japan
| | - K Aogi
- School of Medicine, Kyorin University, Tokyo, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan; Jichi Medical University, Tochigi, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Aichi, Japan; School of Public Health, University of Tokyo, Tokyo, Japan; Tohoku University School of Medicine, Miyagi, Japan; Hamamatsu Oncology Center, Shizuoka, Japan; Kansai Rosai Hospital, Hyogo, Japan; Aihara Hospital, Osaka, Japan
| | - Y Hozumi
- School of Medicine, Kyorin University, Tokyo, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan; Jichi Medical University, Tochigi, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Aichi, Japan; School of Public Health, University of Tokyo, Tokyo, Japan; Tohoku University School of Medicine, Miyagi, Japan; Hamamatsu Oncology Center, Shizuoka, Japan; Kansai Rosai Hospital, Hyogo, Japan; Aihara Hospital, Osaka, Japan
| | - H Mukai
- School of Medicine, Kyorin University, Tokyo, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan; Jichi Medical University, Tochigi, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Aichi, Japan; School of Public Health, University of Tokyo, Tokyo, Japan; Tohoku University School of Medicine, Miyagi, Japan; Hamamatsu Oncology Center, Shizuoka, Japan; Kansai Rosai Hospital, Hyogo, Japan; Aihara Hospital, Osaka, Japan
| | - H Iwata
- School of Medicine, Kyorin University, Tokyo, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan; Jichi Medical University, Tochigi, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Aichi, Japan; School of Public Health, University of Tokyo, Tokyo, Japan; Tohoku University School of Medicine, Miyagi, Japan; Hamamatsu Oncology Center, Shizuoka, Japan; Kansai Rosai Hospital, Hyogo, Japan; Aihara Hospital, Osaka, Japan
| | - I Yokota
- School of Medicine, Kyorin University, Tokyo, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan; Jichi Medical University, Tochigi, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Aichi, Japan; School of Public Health, University of Tokyo, Tokyo, Japan; Tohoku University School of Medicine, Miyagi, Japan; Hamamatsu Oncology Center, Shizuoka, Japan; Kansai Rosai Hospital, Hyogo, Japan; Aihara Hospital, Osaka, Japan
| | - T Yamaguchi
- School of Medicine, Kyorin University, Tokyo, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan; Jichi Medical University, Tochigi, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Aichi, Japan; School of Public Health, University of Tokyo, Tokyo, Japan; Tohoku University School of Medicine, Miyagi, Japan; Hamamatsu Oncology Center, Shizuoka, Japan; Kansai Rosai Hospital, Hyogo, Japan; Aihara Hospital, Osaka, Japan
| | - Y Ohashi
- School of Medicine, Kyorin University, Tokyo, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan; Jichi Medical University, Tochigi, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Aichi, Japan; School of Public Health, University of Tokyo, Tokyo, Japan; Tohoku University School of Medicine, Miyagi, Japan; Hamamatsu Oncology Center, Shizuoka, Japan; Kansai Rosai Hospital, Hyogo, Japan; Aihara Hospital, Osaka, Japan
| | - T Watanabe
- School of Medicine, Kyorin University, Tokyo, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan; Jichi Medical University, Tochigi, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Aichi, Japan; School of Public Health, University of Tokyo, Tokyo, Japan; Tohoku University School of Medicine, Miyagi, Japan; Hamamatsu Oncology Center, Shizuoka, Japan; Kansai Rosai Hospital, Hyogo, Japan; Aihara Hospital, Osaka, Japan
| | - Y Takatsuka
- School of Medicine, Kyorin University, Tokyo, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan; Jichi Medical University, Tochigi, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Aichi, Japan; School of Public Health, University of Tokyo, Tokyo, Japan; Tohoku University School of Medicine, Miyagi, Japan; Hamamatsu Oncology Center, Shizuoka, Japan; Kansai Rosai Hospital, Hyogo, Japan; Aihara Hospital, Osaka, Japan
| | - T Aihara
- School of Medicine, Kyorin University, Tokyo, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan; Jichi Medical University, Tochigi, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Aichi, Japan; School of Public Health, University of Tokyo, Tokyo, Japan; Tohoku University School of Medicine, Miyagi, Japan; Hamamatsu Oncology Center, Shizuoka, Japan; Kansai Rosai Hospital, Hyogo, Japan; Aihara Hospital, Osaka, Japan
| |
Collapse
|
28
|
Imoto S, Sakemura N, Kamma H, Nakatsura T. P1-01-10: Immune Suppression of Regulatory T Cells and M2 Macrophage in Breast Cancer Patients. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p1-01-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Recent multi-disciplinary treatments of breast cancer (BC) could decrease the mortality rate, but successful immune therapy remains uncertain. To explore new strategy of immune therapy of BC, we are investigating about host-tumor immune response in BC patients. Materials and methods: Tumor tissue specimens and peripheral blood mononuclear cells (PBMC) were obtained from early and advanced BC patients. PBMC were also collected from healthy volunteers. Regulatory T (Treg) cells were examined by counting CD4+CD25highCD127low/−cells in PBMC with flow cytometry analysis. Immunohistochemical evaluation of tumor specimens was performed with monoclonal antibodies of HLA-ABC and DR, CD56, CD68, CD83, and CD163. The number of stained cells was analyzed using a semiquantitative ordinal scale ranging from 0 to 3 (0, +/−, ++, +++). Results: HLA-ABC and DR were stained negative in 44% and 82% of 50 BC cases. When host-tumor immune response were compared between 38 early BC cases and 12 advanced BC cases, numbers of CD68-positive cells significantly increased in peripheral tumor tissues of advanced BC cases than in those of early BC cases (92% versus 53%). CD163-positive tumor cells were also detected more frequently in advanced BC cases than in early BC cases (75% versus 16%). There were no significant differences of distribution of CD4, CD8, CD56, and CD83-positive cells in early and advanced BC cases. Treg cells in PBMC significantly increased in percentage of the population in 37 BC patients than in 21 healthy volunteers (4.2% versus 2.5% of CD4-positive cells at mean value). Interestingly, Treg cells decreased in percentage of the population in 36 postoperative BC patients. Conclusions: Our results suggest that Treg cells render BC patients under immune suppression and M2 macrophage plays an important role of tumor progression. Targeted therapy against M2 macrophage may be a promising strategy of breast cancer.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-01-10.
Collapse
Affiliation(s)
- S Imoto
- 1School of Medicine, Kyorin University, Mitaka, Japan; Research Center Organization, National Cancer Center Hospital East, Kashiwa, Japan
| | - N Sakemura
- 1School of Medicine, Kyorin University, Mitaka, Japan; Research Center Organization, National Cancer Center Hospital East, Kashiwa, Japan
| | - H Kamma
- 1School of Medicine, Kyorin University, Mitaka, Japan; Research Center Organization, National Cancer Center Hospital East, Kashiwa, Japan
| | - T Nakatsura
- 1School of Medicine, Kyorin University, Mitaka, Japan; Research Center Organization, National Cancer Center Hospital East, Kashiwa, Japan
| |
Collapse
|
29
|
Sakemura N, Nakatsugawa M, Ito H, Isaka H, Imi K, Tazaki E, Miyamoto K, Wada N, Imoto S, Nakatsura T. P1-01-11: CD4+CD25highCD127low/− Regulatory T Cells Have Immunosuppressive Function in Patients with Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p1-01-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
CD4+CD25highFoxp3+ regulatory T cells play a central role in self-tolerance and suppress antitumor immune response. Recent studies have shown that low levels of the IL-7 receptor (CD127) are expressed on CD4+CD25highFoxp3+ regulatory T cells surfaces and the expression of CD127 is inversely correlated with the suppressive function of CD4+CD25high regulatory T cells. We evaluated the frequency of CD4+CD25highCD127low/− T cells in peripheral blood lymphocytes of 72 breast cancer patients and 21 healthy volunteers. The expression of Foxp3 mRNA was inversely correlated with the CD127 expression and correlated with CD25 expression. The frequency of CD4+CD25highCD127low/− T cells in breast cancer patients was significantly higher than that of healthy volunteers (p=0.0045). CD4+CD25highCD127low/− T cells were increased in hormone receptor negative patients and HER2 positive patients, but no statistical significant was observed in stage progression. In addition, the frequency of CD4+CD25highCD127low/− T cells decreased after curative resection in breast cancer patients (p=0.005). CD4+CD25highCD127low/−T cells also suppress proliferation of autologous CD4+CD25− helper T cells and CD8+ cytotoxic T cells in CFSE-based cell proliferation assay. These findings suggest that CD4+CD25highCD127low/− T cells a useful marker for regulatory T cells in breast cancer. Circulative peripheral regulatory T cells may participate in immune tolerance to breast carcinoma.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-01-11.
Collapse
Affiliation(s)
- N Sakemura
- 1Graduate School of Medicine, Kyorin University, Mitaka Tokyo, Japan; National Cancer Research Center Hospital East, Kashiwa Chiba, Japan
| | - M Nakatsugawa
- 1Graduate School of Medicine, Kyorin University, Mitaka Tokyo, Japan; National Cancer Research Center Hospital East, Kashiwa Chiba, Japan
| | - H Ito
- 1Graduate School of Medicine, Kyorin University, Mitaka Tokyo, Japan; National Cancer Research Center Hospital East, Kashiwa Chiba, Japan
| | - H Isaka
- 1Graduate School of Medicine, Kyorin University, Mitaka Tokyo, Japan; National Cancer Research Center Hospital East, Kashiwa Chiba, Japan
| | - K Imi
- 1Graduate School of Medicine, Kyorin University, Mitaka Tokyo, Japan; National Cancer Research Center Hospital East, Kashiwa Chiba, Japan
| | - E Tazaki
- 1Graduate School of Medicine, Kyorin University, Mitaka Tokyo, Japan; National Cancer Research Center Hospital East, Kashiwa Chiba, Japan
| | - K Miyamoto
- 1Graduate School of Medicine, Kyorin University, Mitaka Tokyo, Japan; National Cancer Research Center Hospital East, Kashiwa Chiba, Japan
| | - N Wada
- 1Graduate School of Medicine, Kyorin University, Mitaka Tokyo, Japan; National Cancer Research Center Hospital East, Kashiwa Chiba, Japan
| | - S Imoto
- 1Graduate School of Medicine, Kyorin University, Mitaka Tokyo, Japan; National Cancer Research Center Hospital East, Kashiwa Chiba, Japan
| | - T Nakatsura
- 1Graduate School of Medicine, Kyorin University, Mitaka Tokyo, Japan; National Cancer Research Center Hospital East, Kashiwa Chiba, Japan
| |
Collapse
|
30
|
Saigo K, Takenokuchi M, Hiramatsu Y, Tada H, Hishita T, Takata M, Misawa M, Imoto S, Imashuku S. Oxidative Stress Levels in Myelodysplastic Syndrome Patients: Their Relationship to Serum Ferritin and Haemoglobin Values. J Int Med Res 2011; 39:1941-5. [DOI: 10.1177/147323001103900539] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Reactive oxygen species (ROS) and serum ferritin levels are both considered to be important biological factors in the pathogenesis of myelodysplastic syndrome (MDS). This study evaluated the levels of ROS in 40 patients with MDS (19 males and 21 females) using the Free Radical Analytical System, FRAS4, and derivatives of reactive oxygen metabolite kits. The patients' mean age was 67.3 years (range 58–86 years). The sera of 34 (85%) patients exhibited higher levels of oxidative stress than the reference range. There was a positive correlation between ROS levels and serum ferritin levels, and a negative correlation between ROS levels and haemoglobin levels. There was a negative relationship between serum haemoglobin and ferritin levels. The results indicated that iron accumulation or severe anaemia could contribute to oxidative stress in MDS patients. Iron chelation and antioxidant therapy may be suitable for the management of MDS.
Collapse
Affiliation(s)
- K Saigo
- Faculty of Pharmacological Sciences, Himeji Dokkyo University, Himeji, Hyogo, Japan
| | - M Takenokuchi
- Faculty of Pharmacological Sciences, Himeji Dokkyo University, Himeji, Hyogo, Japan
| | - Y Hiramatsu
- Department of Haematology and Oncology, Himeji Red Cross Hospital, Himeji, Hyogo, Japan
| | - H Tada
- Department of Haematology and Oncology, Himeji Red Cross Hospital, Himeji, Hyogo, Japan
| | - T Hishita
- Department of Haematology, Himeji Medical Centre, Himeji, Hyogo, Japan
| | - M Takata
- Department of Medicine, Kakogawa Municipal Hospital, Kakogawa, Hyogo, Japan
| | - M Misawa
- Department of Haematology, Akoh Central Hospital, Akoh, Hyogo, Japan
| | - S Imoto
- Faculty of Health Science, Kobe Tokiwa University, Kobe, Hyogo, Japan
| | - S Imashuku
- Department of Paediatrics, Takasago Seibu Hospital, Takasago, Hyogo, Japan
| |
Collapse
|
31
|
Hojo T, Kinoshita T, Wada N, Imoto S, Tamura N, Nagao T, Ando M, Katsumata N, Fujiwara Y. Abstract P1-12-07: Neo-Adjuvant Exemestane in Post Menopausal Estrogen and/or Progesterone Receptor Positive Breast Cancer: A Randomized Phase II Trial To Investigate Optimal Duration (4 Month Versus 6 Month) of Preoperative Endocrine Therapy (PTEX46 Trial). Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-12-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Since the 1990s, primary endocrine therapy has been considered the gold standard in the adjuvant and metastatic treatment settings for estrogen and/or progesterone receptor (ER and/or PgR) positive breast cancer. This therapy has also been shown to be effective as neo-adjuvant endocrine therapy in these indications. In recent years, the focus of clinical interest has shifted to the third-generation aromatase inhibitors from tamoxifen. The optimal treatment duration time and causal relationship between neo-adjuvant endocrine therapy and survival, however, are not clear. We therefore conducted the present study to investigate the potential benefits of neo-adjuvant exemestane (E) therapy with the goal of identifying the optimal treatment duration (4 months versus 6 months).
Methods: Conducted at three hospitals in Japan, this study was a multicenter, randomized phase II trial of pre-operative E treatment in postmenopausal women with untreated primary breast cancer. Fifty postmenopausal women with ER positive and/or PgR positive invasive breast cancer were randomly assigned to E (25 mg/day) for 4 months (4 mo) or E (25 mg/day) for 6 months (6 mo). All patient data were collected by UMIN and were analyzed by the National Cancer Center in Japan. Tumor regression (by clinical examination, ultrasound, and MRI), pathological response, shift towards breast-conserving surgery, and safety assessments were the main outcome measures.
Results: Of the 50 patients that enrolled, 28 patients had undergone surgery. The mean ages in the 4 mo and 6 mo treatment groups were 66.7 years and 66.8 years, respectively. No significant differences in the patient characteristics were found in the two groups. The response rates (partial or complete responses) by clinical examination in the 4 mo and 6 mo groups were 37.5% and 50%, respectively. Pathological responses (minimal response or better) were found in 13.3% and 41.7% of patients and a partial mastectomy was performed in 50.0% and 58.3% of patients after 4 mo and 6 mo, respectively.
Conclusion: To date, the results of this study demonstrate that treatment with E for 6 mo was more efficacious than treatment with E for 4 mo. Further work is in progress to obtain data from additional patients and to identify the optimal duration of neo-adjuvant E.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-12-07.
Collapse
Affiliation(s)
- T Hojo
- National Cancer Center Hospital; National Cancer Center Hospital East; Kyorin University Hospital
| | - T Kinoshita
- National Cancer Center Hospital; National Cancer Center Hospital East; Kyorin University Hospital
| | - N Wada
- National Cancer Center Hospital; National Cancer Center Hospital East; Kyorin University Hospital
| | - S Imoto
- National Cancer Center Hospital; National Cancer Center Hospital East; Kyorin University Hospital
| | - N Tamura
- National Cancer Center Hospital; National Cancer Center Hospital East; Kyorin University Hospital
| | - T Nagao
- National Cancer Center Hospital; National Cancer Center Hospital East; Kyorin University Hospital
| | - M Ando
- National Cancer Center Hospital; National Cancer Center Hospital East; Kyorin University Hospital
| | - N Katsumata
- National Cancer Center Hospital; National Cancer Center Hospital East; Kyorin University Hospital
| | - Y. Fujiwara
- National Cancer Center Hospital; National Cancer Center Hospital East; Kyorin University Hospital
| |
Collapse
|
32
|
Bouike Y, Imoto S, Mabuchi O, Kokubunji A, Kai S, Okada M, Taniguchi R, Momose S, Uchida S, Nishio H. Infectivity of HBV DNA positive donations identified in look-back studies in Hyogo-Prefecture, Japan. Transfus Med 2010; 21:107-15. [PMID: 21118317 DOI: 10.1111/j.1365-3148.2010.01057.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
AIMS/OBJECTIVES To clarify transfusion incidence of hepatitis B virus (HBV) infected blood negative for mini pool-nucleic acid amplification testing (MP-NAT). BACKGROUND Japanese Red Cross (JRC) blood centres screen donated blood to avoid contamination with HBV. However, a low copy number of HBV may be overlooked. METHODS/MATERIALS In Hyogo-Prefecture, JRC blood centres screened 787 695 donations for HBV from April 2005 to March 2009. Of these, 685 844 were donations from the repeat donors. To detect the donors with HBV, serological tests, MP-NAT and/or individual donation (ID)-NAT were performed. To detect the recipients with transfusion-transmitted HBV infection (TTHBI), serological analysis and/or ID-NAT were performed. RESULTS In this study, 265 of the 685 844 repeat donations were serologically and/or MP-NAT positive for HBV. Their repository samples from the previous donation were examined in a look-back study; 13 of the 265 repository samples proved ID-NAT positive. Twelve recipients were transfused with HBV-infected blood components derived from 10 of the 13 HBV-infected donors. Only 1 of the 12 recipients was identified as TTHBI case. Seven of the 12 recipients escaped from our follow-up study and 4 recipients were negative for HBV during the observation period. CONCLUSION On the basis of the look-back study among the repeat donors in Hyogo-Prefecture, Japan, donations with HBV-infected blood negative for MP-NAT occurred with a frequency of 13 in 685 844 donations (∼1/53 000 donations). However, more than half of the recipients transfused with HBV-infected blood negative for MP-NAT could not be followed up. It is necessary to establish a more cautious follow-up system.
Collapse
Affiliation(s)
- Y Bouike
- Department of Science and Technology, Japanese Red Cross Hyogo Blood Centre, Chuo-ku, Kobe, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
We simulated the early phase of the 2009 influenza A(H1N1) pandemic and assessed the effectiveness of public health interventions in Japan. We show that the detection rate of border quarantine was low and the timing of the intervention was the most important factor involved in the control of the pandemic, with the maximum reduction in daily cases obtained after interventions started on day 6 or 11. Early interventions were not always effective.
Collapse
Affiliation(s)
- H Sato
- Department of Medical Informatics, National Defense Medical College Hospital, Saitama, Japan.
| | | | | | | | | | | |
Collapse
|
34
|
Imoto S, Kawamura K, Tokumine Y, Araki N, Akita S, Nishimura C, Inaba H, Saigo K, Mabuchi O, Okazaki H. Acute non-hemolytic transfusion reactions and HLA class I antibody: advantages of solid phase assay compared with conventional complement-dependent assay. Transfus Med 2009; 20:95-103. [PMID: 19883399 PMCID: PMC2860765 DOI: 10.1111/j.1365-3148.2009.00972.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
To evaluate the specific reactivity of HLA Class I antibodies (HLA-I Abs) in acute non-hemolytic transfusion reactions (ANHTRs) using solid phase assays (SPAs) and conventional complement-dependent lymphocyte cytotoxicity test (LCT). ANHTRs are major issues in transfusion medicine. Anti-leukocyte antibodies have been implicated as one of the causative agents of transfusion-related acute lung injury (TRALI) and febrile reaction. Antibodies to HLA Class I and/or Class II (HLA Abs) have been intensively studied using SPAs for TRALI, but not for febrile reaction. About 107 patients and 186 donors associated with ANHTRs were screened for HLA Abs by SPAs such as enzyme-linked immunosorbent assay (ELISA) and the Luminex method. When HLA-I Ab was detected, its specific reactivity was evaluated by comparing its specificity identified by the Luminex method using recombinant HLA molecules and cognate HLA antigens (Ags), as well as LCT with or without anti-human globulin (AHG). The incidences of HLA Abs were as high as 32·7% of patients' serum samples and 16% of donors' serum samples. The incidence of HLA-I Abs did not differ significantly between cases of febrile and allergic reactions. However, HLA-I Abs associated with febrile reaction showed a significantly higher rate of possessing specific reactivity to cognate HLA Ags than those associated with allergic reactions. In addition, the Luminex method enabled the detection of HLA-I Abs much earlier than AHG-LCT in serum samples from a patient with febrile reaction and platelet transfusion refractoriness (PTR). SPAs seem more useful than AHG-LCT for evaluating reactivity of antibodies in ANHTR cases.
Collapse
Affiliation(s)
- S Imoto
- Japanese Red Cross Hyogo Blood Center, Kobe, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Imoto S, Morita S, Kitajima M, Aikou T, Kitagawa Y. Early recurrence of breast cancer after sentinel node navigation surgery: A multicenter prospective study in Japan. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e11530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e11530 Background: To assess lymphatic mapping technique and prognosis after sentinel node navigation surgery (SNNS), the Japanese society for SNNS conducted a non-randomized multi-center prospective study on SNNS in early breast cancer. Primary endpoint is to evaluate the success rate and adverse events of SNNS, and secondary endpoint is to observe the outcome of patients who underwent SNNS during 5 years. Methods: We demonstrated the results of primary endpoint at 2007 ASCO annual meeting (#606). Fourteen hundred and sixty-eight cases had pre-registration from 65 investigators at 23 institutions between July 2004 and October 2005. As 46 cases were withdrawn for some reasons and 11 cases were diagnosed as benign disease, 1,411 cases were entered in this study and will be observed until 2010. At this meeting, early recurrence at 3 years follow-up is reported. Results: As of June 2008, 38 of the 1,138 cases (3%) treated with SNNS alone and 16 of the 258 (6%) cases treated with SNNS followed by axillary lymph node dissection (ALND) relapsed. Seven cases died of disease. From the patient background, 50 cases had invasive ductal carcinoma, one had non-invasive ductal carcinoma, and three had special type. Thirty-three cases had negative nodes, 3 had micrometastatic nodes, and 18 had macrometastatic nodes. Fifty-two cases received chemotherapy and/or endocrine therapy. Regional recurrence including axillary, parasternal, and/or supraclavicular nodes was found in 11 cases after SNNS and in 2 cases after SNNS followed by ALND. Conclusions: Annual regional recurrence rate after SNNS was about 0.3%. SNNS in breast cancer is reliable to optimize surgical management in the axilla without increase of regional recurrence. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Imoto
- School of Medicine, Kyorin University, Mitaka, Japan; Yokohama City University Medical Center, Yokohama, Japan; International University of Health and Welfare, Tokyo, Japan; Kagoshima University Faculty of Medicine, Kagoshima, Japan; School of Medicine, Keio University, Tokyo, Japan; Japanese Society Investigators for Sentinel Node Navigation Surgery
| | - S. Morita
- School of Medicine, Kyorin University, Mitaka, Japan; Yokohama City University Medical Center, Yokohama, Japan; International University of Health and Welfare, Tokyo, Japan; Kagoshima University Faculty of Medicine, Kagoshima, Japan; School of Medicine, Keio University, Tokyo, Japan; Japanese Society Investigators for Sentinel Node Navigation Surgery
| | - M. Kitajima
- School of Medicine, Kyorin University, Mitaka, Japan; Yokohama City University Medical Center, Yokohama, Japan; International University of Health and Welfare, Tokyo, Japan; Kagoshima University Faculty of Medicine, Kagoshima, Japan; School of Medicine, Keio University, Tokyo, Japan; Japanese Society Investigators for Sentinel Node Navigation Surgery
| | - T. Aikou
- School of Medicine, Kyorin University, Mitaka, Japan; Yokohama City University Medical Center, Yokohama, Japan; International University of Health and Welfare, Tokyo, Japan; Kagoshima University Faculty of Medicine, Kagoshima, Japan; School of Medicine, Keio University, Tokyo, Japan; Japanese Society Investigators for Sentinel Node Navigation Surgery
| | - Y. Kitagawa
- School of Medicine, Kyorin University, Mitaka, Japan; Yokohama City University Medical Center, Yokohama, Japan; International University of Health and Welfare, Tokyo, Japan; Kagoshima University Faculty of Medicine, Kagoshima, Japan; School of Medicine, Keio University, Tokyo, Japan; Japanese Society Investigators for Sentinel Node Navigation Surgery
| |
Collapse
|
36
|
EL-Sabagh M, Imoto S, Yukizane K, Yokotani A, Sugino T, Obitsu T, Taniguchi K. Net Portal Fluxes of Nitrogen Metabolites in Holstein Steers Fed Diets Containing Different Dietary Ratios of Whole-crop Corn Silage and Alfalfa Hay. Asian Australas J Anim Sci 2009. [DOI: 10.5713/ajas.2009.80414] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
37
|
Sakata M, Ikeda T, Imoto S, Jinno H, Kitagawa Y. 0034 Chemopreventive effect of green tea extract and tamoxifen on mouse mammary preneoplastic lesions. Breast 2009. [DOI: 10.1016/s0960-9776(09)70083-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
38
|
Imoto S, Takatsuka Y, Fujiwara Y, Inaji H, Ikeda T, Cataliotti L, Buzdar A, Noguchi S. 0181 PROACT: A randomised study comparing anastrozole with tamoxifen as neoadjuvant and adjuvant treatment in postmenopausal women with locally advanced breast cancer - a Japanese subgroup analysis. Breast 2009. [DOI: 10.1016/s0960-9776(09)70204-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
39
|
Imoto S, Wada N, Sakemura N, Murata Y, Hasebe T. Feasibility study on radiofrequency ablation therapy followed by partial mastectomy for stage I breast cancer patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.11583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
40
|
Imoto S, Araki N, Shimada E, Saigo K, Nishimura K, Nose Y, Bouike Y, Hashimoto M, Mito H, Okazaki H. Comparison of acute non-haemolytic transfusion reactions in female and male patients receiving female or male blood components. Transfus Med 2008; 17:455-65. [PMID: 18067650 PMCID: PMC2440557 DOI: 10.1111/j.1365-3148.2007.00802.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
To study the relationship between antibodies detected in patients’ and/or donors’ sera and the clinical features of acute non-haemolytic transfusion reactions (ANHTRs), and to determine any gender-related difference. ANHTRs range from urticaria to transfusion-related acute lung injury (TRALI). Antibodies to human leukocyte antigen (HLA), granulocytes, platelets, and/or plasma proteins are implicated in some of the ANHTRs. A higher antibody positivity is expected for females than for males. A comparative study of ANHTRs for antibody positivity and their clinical features between females and males for both patients and donors is helpful for characterizing ANHTRs including TRALI more clearly, but such studies are few and outdated. Two hundred and twenty-three ANHTR cases reported by 45 hospitals between October 2000 and July 2005 were analysed. The patients and 196 donors of suspect blood products were screened for antibodies to HLA Class I, HLA Class II, granulocytes, and platelets. The patients were also screened for anti-plasma protein antibodies. The types and severity of ANHTR did not differ significantly between female and male patients. The frequency of the anti-HLA antibodies, but not that of the non-HLA antibodies, was significantly higher in females. Non-HLA antibodies were significantly associated with severe reactions in females. All the TRALI cases had predisposing risk factors for acute lung injury, and 60% of the cases showed anti-leucocyte antibodies. Although the anti-HLA antibodies were detected more frequently in females than males, no significant association of ANHTRs including TRALI with gender, not only for patients, but also for donors, could be shown in this study.
Collapse
Affiliation(s)
- S Imoto
- Hyogo Red Cross Blood Center, Kobe, Japan.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Muromoto R, Sekine Y, Imoto S, Ikeda O, Okayama T, Sato N, Matsuda T. BART is essential for nuclear retention of STAT3. Int Immunol 2008; 20:395-403. [DOI: 10.1093/intimm/dxm154] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Wada N, Sakemura N, Imoto S, Hasebe T, Ochiai A, Moriyama N. Sentinel node biopsy in primary breast cancer: Radioactive detection and metastatic disease. Eur J Surg Oncol 2007; 33:691-5. [PMID: 17258879 DOI: 10.1016/j.ejso.2006.10.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2006] [Accepted: 10/03/2006] [Indexed: 02/06/2023] Open
Abstract
AIM To examine the relationship between the intensity of the radioactive counts and the presence of tumor metastasis in sentinel lymph nodes (SLNs) in order to correctly identify the number of SLNs to be removed. PATIENTS AND METHODS Five hundred three breast cancer patients with successful radioisotope localization of SLNs using the combined blue dye and radioisotope method were analyzed. SLN biopsy was continued until all the blue-stained and radioactive nodes were removed. RESULTS The mean number of harvested SLNs was 1.7+/-0.9, and the number of radioactive SLNs among the harvested nodes was 1.6+/-0.8. SLN metastasis was found in 123 of the 503 cases. The metastasis was detected in the SLN with the highest radioactive count (the hottest SLN) in 94 of the 123 cases with positive SLNs. The positive rate in the hottest SLN was 89% in 61 cases with a single radioactive SLN, and 65% in 62 cases with multiple radioactive SLNs. Of the 29 cases with positivity in other than the hottest SLNs, the metastasis was detected in the second hottest SLN in 16 cases, in the third hottest SLN in one case, in a mixture of negative radioactive SLNs and blue-dye-stained in four cases, and in the negative SLNs and positive non-SLNs (false-negative) in eight cases. Of 123 node-positive cases, 111 cases had metastasis that was detected within the first three hottest SLNs. CONCLUSIONS These data suggest that lymph node metastasis may not always be detected in the hottest SLN. Thus, in practice, all radioactive and/or blue-dye-stained nodes should be removed for further examination.
Collapse
Affiliation(s)
- N Wada
- Breast Surgery Division, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
| | | | | | | | | | | |
Collapse
|
43
|
Imoto S, Kitajima M, Aikou T, Kitagawa Y. Multi-center prospective study on sentinel node navigation surgery in early breast cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
606 Background: Sentinel node navigation surgery (SNNS) is a standard technique to identify lymph node metastases in clinically node-negative breast cancer. However, the dye and radiopharmaceuticals for lymphatic mapping commonly used in Western countries are not available in Japan. Methods: To assess the optimal lymphatic mapping and the outcome after SNNS, the Japanese society for SNNS conducted a non-randomized multi-center prospective study on SNNS in early breast cancer. Primary endpoint is to evaluate the success rates and adverse events associated with various lymphatic mapping and SNNS, and secondary endpoint is to observe the outcome of patients who underwent SNNS during 5 years. After the protocol was approved by institutional review board, SNNS had been registered between July 2004 and October 2005. Results: Fourteen hundred and sixty-eight cases had pre-registration from 65 investigators at 23 institutions. As 46 cases were withdrawn for some reasons and 11 cases were diagnosed as benign disease, 1,411 cases were finally entered in this study. Dyes used for lymphatic mapping were indigocarmine, indocyanin green, patent blue, and isosulfun blue, and radiopharmaceuticals were 99m-technetium-labelled tin colloid, human serum albumin, and phytate. In 19 cases, superparamagnetic iron oxide was used for MRI- guided SNNS. As of December 2006, 98% of clinical report forms were analyzed. Dye-guided SNNS was performed in 240 cases, radio-guided SNNS in 56 cases, and combined method in 1,016 cases. Overall success rate was 99%. SNNS alone was treated in 1,138 cases (82%) and SNNS followed by axillary lymph node dissection in 258 cases (12%). Breast-conserving surgery was undergone in 1,175 cases (85%) and total mastectomy in 217 cases (15%). Dye-induced allergic adverse events were not reported. Postoperative adverse events of bleeding, wound infection and seroma were observed in about 1 % of cases, respectively. Conclusions: Dye-guided and/or radio-guided SNNS proved reliable for lymphatic mapping in breast cancer. The prognosis of all cases will be observed until 2010. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Imoto
- National Cancer Center Hospital East, Kashiwa, Japan; School of Medicine, Keio University, Tokyo, Japan; Kagoshima University Graduate School of Medicine, Kagoshima, Japan
| | - M. Kitajima
- National Cancer Center Hospital East, Kashiwa, Japan; School of Medicine, Keio University, Tokyo, Japan; Kagoshima University Graduate School of Medicine, Kagoshima, Japan
| | - T. Aikou
- National Cancer Center Hospital East, Kashiwa, Japan; School of Medicine, Keio University, Tokyo, Japan; Kagoshima University Graduate School of Medicine, Kagoshima, Japan
| | - Y. Kitagawa
- National Cancer Center Hospital East, Kashiwa, Japan; School of Medicine, Keio University, Tokyo, Japan; Kagoshima University Graduate School of Medicine, Kagoshima, Japan
| |
Collapse
|
44
|
Sekine Y, Ikeda O, Hayakawa Y, Tsuji S, Imoto S, Aoki N, Sugiyama K, Matsuda T. DUSP22/LMW-DSP2 regulates estrogen receptor-alpha-mediated signaling through dephosphorylation of Ser-118. Oncogene 2007; 26:6038-49. [PMID: 17384676 DOI: 10.1038/sj.onc.1210426] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
In the previous study, we demonstrated the involvement of dual specificity phosphatase 22 (DUSP22/LMW-DSP2) in regulating the leukemia inhibitory factor/interleukin-6/signal transducer and activator of transcription 3-mediated signaling pathway. In this study, we show beta-estradiol (E2)-induced DUSP22 mRNA expression in estrogen receptor alpha (ERalpha)-positive breast cancer cells, whereas E2-induced phosphorylation and activation of ERalpha was suppressed by overexpression of DUSP22 but not catalytically inactive mutants. Furthermore, small-interfering RNA-mediated reduction of DUSP22 expression enhanced ERalpha-mediated transcription and endogenous gene expression. In fact, DUSP22 associated with ERalpha in vivo and both endogenous proteins interacted in ERalpha-positive breast cancer T47D cells. These results strongly suggest that DUSP22 acts as a negative regulator of the ERalpha-mediated signaling pathway.
Collapse
Affiliation(s)
- Y Sekine
- Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Imoto S, Ochiai A, Okumura C, Wada N, Hasebe T. Impact of isolated tumor cells in sentinel lymph nodes detected by immunohistochemical staining. Eur J Surg Oncol 2006; 32:1175-9. [PMID: 16979316 DOI: 10.1016/j.ejso.2006.08.006] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2006] [Accepted: 08/14/2006] [Indexed: 11/19/2022] Open
Abstract
AIM Isolated tumor cells (ITCs) in lymph nodes are defined histologically as node-negative. The clinical impact of ITCs in sentinel lymph nodes (SLNs) remains unclear. We report the prognosis of breast cancer patients with ITC-positive SLNs detected by immunohistochemical staining. PATIENTS AND METHODS One hundred and sixty-five breast cancer patients with histologically negative SLNs were seen between January 1998 and December 2000. In 69 patients, sentinel node biopsy (SNB) was immediately followed by axillary lymph node dissection, and 96 had undergone SNB alone. Permanent sections of 301 SLNs were re-examined after hematoxylin-eosin staining and cytokeratin 19 immunohistochemical staining. RESULTS ITCs were found in 18 SLNs of 17 patients and a micrometastasis was found in one SLN of one patient. As of November 2005, only one patient with ITCs in one SLN had supraclavicular lymph node recurrence. In contrast, 18 of the 147 patients with negative SLNs had tumor recurrence. Surgical management of the axilla had no influence on recurrence-free survival in all of the patients. CONCLUSION This study shows that breast cancer patients with ITC-positive SLNs should be clinically managed as node-negative patients.
Collapse
Affiliation(s)
- S Imoto
- Breast Surgery Division, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
| | | | | | | | | |
Collapse
|
46
|
Wada N, Imoto S. The hottest sentinel lymph node for breast cancer dose not always contain metastasis. EJC Suppl 2006. [DOI: 10.1016/s1359-6349(06)80150-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
47
|
Wada N, Imoto S, Yamauchi C, Hasebe T, Ochiai A. Predictors of tumour involvement in remaining axillary lymph nodes of breast cancer patients with positive sentinel lymph node. Eur J Surg Oncol 2006; 32:29-33. [PMID: 16269227 DOI: 10.1016/j.ejso.2005.08.010] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2005] [Revised: 08/03/2005] [Accepted: 08/18/2005] [Indexed: 10/25/2022] Open
Abstract
AIMS To characterize the various clinicopathologic features in cases of breast cancer with positive sentinel lymph nodes (SLNs), in order to determine factors that might help in predicting the involvement of the non-SLNs. METHODS A retrospective database review was performed of 726 breast cancer patients with stage 0-II, in whom SLNs were successfully identified. One hundred eighty-five of these patients showed positive SLNs, and subsequently underwent axillary lymph node dissection (ALND). These cases were divided into two groups based on the presence or absence of metastases in the non-SLNs, i.e. positive non-SLNs (NSLN+; 81 cases) and negative non-SLNs (NSLN-; 104 cases). RESULTS Multivariate analysis revealed that a larger size of the primary tumour (>2.0cm), presence of lymphatic invasion, larger size of the largest SLN metastasis (>2mm), and a 100% metastatic rate in the SLNs (number of positive SLNs/number of harvested SLNs) were significantly associated with NSLN+. Among the cases in which all the four factors were present, 73% (30/41) were found to have NSLN+. CONCLUSION We found four independent predictors in relation to non-SLN metastasis. Although these factors might be useful for determining the need of additional ALND, it would seem that even the presence of all of these four factors in combination may be insufficient to safely omit ALND. Thus, until further evidence is accumulated from the results of large clinical trials, ALND would still be recommended for patients with SLN metastasis.
Collapse
Affiliation(s)
- N Wada
- Breast Surgery Division, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
| | | | | | | | | |
Collapse
|
48
|
Tsuda H, Kurozumi M, Akiyama F, Sakamoto G, Noguchi S, Takatsuka Y, Watanabe T, Imoto S, Inaji H. Histopathological assessment of anastrozole versus tamoxifen as preoperative treatment in postmenopausal women with T2–4b, N0–2, M0 breast cancer: Results from a randomized, double-blind study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.570] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. Tsuda
- National Defense Medcl Coll, Saitama, Japan; Saitama Cancer Ctr Hosp, Saitama, Japan; Japanese Fdn for Cancer Research, Tokyo, Japan; Japanese Fdn for Cancer Research, Tokyo, Japan; Osaka Univ Medcl Sch, Osaka, Japan; Kansai Rosai Hosp, Kansai, Japan; Intl Univ of Health and Welfare, Tokyo, Japan; National Cancer Ctr Hosp East, Kashiwa, Japan; Osaka Medcl Ctr Cancer & Cardiovascular Dis, Osaka, Japan
| | - M. Kurozumi
- National Defense Medcl Coll, Saitama, Japan; Saitama Cancer Ctr Hosp, Saitama, Japan; Japanese Fdn for Cancer Research, Tokyo, Japan; Japanese Fdn for Cancer Research, Tokyo, Japan; Osaka Univ Medcl Sch, Osaka, Japan; Kansai Rosai Hosp, Kansai, Japan; Intl Univ of Health and Welfare, Tokyo, Japan; National Cancer Ctr Hosp East, Kashiwa, Japan; Osaka Medcl Ctr Cancer & Cardiovascular Dis, Osaka, Japan
| | - F. Akiyama
- National Defense Medcl Coll, Saitama, Japan; Saitama Cancer Ctr Hosp, Saitama, Japan; Japanese Fdn for Cancer Research, Tokyo, Japan; Japanese Fdn for Cancer Research, Tokyo, Japan; Osaka Univ Medcl Sch, Osaka, Japan; Kansai Rosai Hosp, Kansai, Japan; Intl Univ of Health and Welfare, Tokyo, Japan; National Cancer Ctr Hosp East, Kashiwa, Japan; Osaka Medcl Ctr Cancer & Cardiovascular Dis, Osaka, Japan
| | - G. Sakamoto
- National Defense Medcl Coll, Saitama, Japan; Saitama Cancer Ctr Hosp, Saitama, Japan; Japanese Fdn for Cancer Research, Tokyo, Japan; Japanese Fdn for Cancer Research, Tokyo, Japan; Osaka Univ Medcl Sch, Osaka, Japan; Kansai Rosai Hosp, Kansai, Japan; Intl Univ of Health and Welfare, Tokyo, Japan; National Cancer Ctr Hosp East, Kashiwa, Japan; Osaka Medcl Ctr Cancer & Cardiovascular Dis, Osaka, Japan
| | - S. Noguchi
- National Defense Medcl Coll, Saitama, Japan; Saitama Cancer Ctr Hosp, Saitama, Japan; Japanese Fdn for Cancer Research, Tokyo, Japan; Japanese Fdn for Cancer Research, Tokyo, Japan; Osaka Univ Medcl Sch, Osaka, Japan; Kansai Rosai Hosp, Kansai, Japan; Intl Univ of Health and Welfare, Tokyo, Japan; National Cancer Ctr Hosp East, Kashiwa, Japan; Osaka Medcl Ctr Cancer & Cardiovascular Dis, Osaka, Japan
| | - Y. Takatsuka
- National Defense Medcl Coll, Saitama, Japan; Saitama Cancer Ctr Hosp, Saitama, Japan; Japanese Fdn for Cancer Research, Tokyo, Japan; Japanese Fdn for Cancer Research, Tokyo, Japan; Osaka Univ Medcl Sch, Osaka, Japan; Kansai Rosai Hosp, Kansai, Japan; Intl Univ of Health and Welfare, Tokyo, Japan; National Cancer Ctr Hosp East, Kashiwa, Japan; Osaka Medcl Ctr Cancer & Cardiovascular Dis, Osaka, Japan
| | - T. Watanabe
- National Defense Medcl Coll, Saitama, Japan; Saitama Cancer Ctr Hosp, Saitama, Japan; Japanese Fdn for Cancer Research, Tokyo, Japan; Japanese Fdn for Cancer Research, Tokyo, Japan; Osaka Univ Medcl Sch, Osaka, Japan; Kansai Rosai Hosp, Kansai, Japan; Intl Univ of Health and Welfare, Tokyo, Japan; National Cancer Ctr Hosp East, Kashiwa, Japan; Osaka Medcl Ctr Cancer & Cardiovascular Dis, Osaka, Japan
| | - S. Imoto
- National Defense Medcl Coll, Saitama, Japan; Saitama Cancer Ctr Hosp, Saitama, Japan; Japanese Fdn for Cancer Research, Tokyo, Japan; Japanese Fdn for Cancer Research, Tokyo, Japan; Osaka Univ Medcl Sch, Osaka, Japan; Kansai Rosai Hosp, Kansai, Japan; Intl Univ of Health and Welfare, Tokyo, Japan; National Cancer Ctr Hosp East, Kashiwa, Japan; Osaka Medcl Ctr Cancer & Cardiovascular Dis, Osaka, Japan
| | - H. Inaji
- National Defense Medcl Coll, Saitama, Japan; Saitama Cancer Ctr Hosp, Saitama, Japan; Japanese Fdn for Cancer Research, Tokyo, Japan; Japanese Fdn for Cancer Research, Tokyo, Japan; Osaka Univ Medcl Sch, Osaka, Japan; Kansai Rosai Hosp, Kansai, Japan; Intl Univ of Health and Welfare, Tokyo, Japan; National Cancer Ctr Hosp East, Kashiwa, Japan; Osaka Medcl Ctr Cancer & Cardiovascular Dis, Osaka, Japan
| |
Collapse
|
49
|
Hasebe T, Sasaki S, Imoto S, Wada N, Ishii G, Ochiai A. Primary tumour-vessel tumour-nodal tumour classification for patients with invasive ductal carcinoma of the breast. Br J Cancer 2005; 92:847-56. [PMID: 15756255 PMCID: PMC2361891 DOI: 10.1038/sj.bjc.6602353] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
There are many studies that show biological differences between invasive ductal carcinoma (IDC) with and without nodal metastasis, but no prognostic classification taking into consideration any biological differences between them is currently available. We previously investigated the histological characteristics that play an important role in tumour progression of IDCs according to their nodal status, and a new prognostic histological classification, the primary tumour–vessel tumour–nodal tumour (PVN) classification, was devised based on the histological characteristics of IDCs with and without nodal metastasis. Multivariate analyses using the Cox proportional hazard regression models were used to compare the ability of the PVN classification to predict tumour recurrence and death in 393 IDC patients based on the following histological classifications: (1) the pTNM classification, (2) the Nottingham Prognostic Index, (3) the modified Nottingham Prognostic Index, and (4) the histologic grade. In IDCs without nodal metastasis, only the PVN classification significantly increased the hazard rates (HRs) of tumour recurrence and death (P<0.05), independent of the hormone receptor status. Similarly, in IDCs with nodal metastases, only the PVN classification significantly increased the HRs of tumour recurrence and death (P<0.05), independent of the hormone receptor status. We conclude that the PVN prognostic histological classification is the best classification available for IDC of the breast.
Collapse
MESH Headings
- Breast Neoplasms/blood supply
- Breast Neoplasms/classification
- Breast Neoplasms/mortality
- Breast Neoplasms/pathology
- Breast Neoplasms/surgery
- Carcinoma, Ductal, Breast/blood supply
- Carcinoma, Ductal, Breast/classification
- Carcinoma, Ductal, Breast/mortality
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Ductal, Breast/surgery
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Lymphatic Metastasis
- Neoplasm Invasiveness
- Neoplasm Staging
- Neovascularization, Pathologic/pathology
- Recurrence
- Retrospective Studies
- Survival Analysis
- Time Factors
Collapse
Affiliation(s)
- T Hasebe
- Division of Pathology, The National Cancer Center Research Institute East, Kashiwanoha 6-5-1, Kashiwa, Chiba 277-8577, Japan
| | - S Sasaki
- Division of Epidemiology, The National Cancer Center Institute East, Chiba, MD, Japan
| | - S Imoto
- Department of Breast Surgery, The National Cancer Center Hospital East, Chiba, MD, Japan
| | - N Wada
- Department of Breast Surgery, The National Cancer Center Hospital East, Chiba, MD, Japan
| | - G Ishii
- Division of Pathology, The National Cancer Center Research Institute East, Kashiwanoha 6-5-1, Kashiwa, Chiba 277-8577, Japan
| | - A Ochiai
- Division of Pathology, The National Cancer Center Research Institute East, Kashiwanoha 6-5-1, Kashiwa, Chiba 277-8577, Japan
- Division of Pathology, The National Cancer Center Research Institute East, Kashiwanoha 6-5-1, Kashiwa, Chiba 277-8577, Japan. E-mail:
| |
Collapse
|
50
|
de Hoon MJL, Makita Y, Imoto S, Kobayashi K, Ogasawara N, Nakai K, Miyano S. Predicting gene regulation by sigma factors in Bacillus subtilis from genome-wide data. Bioinformatics 2004; 20 Suppl 1:i101-8. [PMID: 15262787 DOI: 10.1093/bioinformatics/bth927] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
MOTIVATION Sigma factors regulate the expression of genes in Bacillus subtilis at the transcriptional level. We assess the accuracy of a fold-change analysis, Bayesian networks, dynamic models and supervised learning based on coregulation in predicting gene regulation by sigma factors from gene expression data. To improve the prediction accuracy, we combine sequence information with expression data by adding their log-likelihood scores and by using a logistic regression model. We use the resulting score function to discover currently unknown gene regulations by sigma factors. RESULTS The coregulation-based supervised learning method gave the most accurate prediction of sigma factors from expression data. We found that the logistic regression model effectively combines expression data with sequence information. In a genome-wide search, highly significant logistic regression scores were found for several genes whose transcriptional regulation is currently unknown. We provide the corresponding RNA polymerase binding sites to enable a straightforward experimental verification of these predictions.
Collapse
Affiliation(s)
- M J L de Hoon
- Human Genome Center, Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, Tokyo, Japan.
| | | | | | | | | | | | | |
Collapse
|